



**FRED HUTCHINSON CANCER CENTER
UNIFORM GUIDANCE FOR FEDERAL AWARDS**

Independent Auditor's Report in Accordance with the
Uniform Guidance for Federal Awards

Year Ended June 30, 2023

**FRED HUTCHINSON CANCER CENTER
UNIFORM GUIDANCE FOR FEDERAL AWARDS**

Table of Contents

	Page(s)
Independent Auditors' Report	1–2
Consolidated Financial Statements:	
Consolidated Statement of Financial Position	3
Consolidated Statement of Activities	4
Consolidated Statement of Cash Flows	5
Notes to Consolidated Financial Statements	6–32
Independent Auditors' Report on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	33–34
Independent Auditors' Report on Compliance for Each Major Federal Program; Report on Internal Control over Compliance; and Report on Schedule of Expenditures of Federal Awards Required by Uniform Guidance	35–37
Schedule of Expenditures of Federal Awards	38–48
Notes to the Schedule of Expenditures of Federal Awards	49
Schedule of Findings and Questioned Costs	50



KPMG LLP
Suite 2800
401 Union Street
Seattle, WA 98101

Independent Auditors' Report

The Board of Directors
Fred Hutchinson Cancer Center:

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the consolidated financial statements of Fred Hutchinson Cancer Center (Fred Hutch), which comprise the consolidated statement of financial position as of June 30, 2023, and the related consolidated statement of activities and cash flows for the year then ended, and the related notes to the consolidated financial statements.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of Fred Hutch as of June 30, 2023, and the changes in its net assets and its cash flows for the year then ended in accordance with U.S. generally accepted accounting principles.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in Government Auditing Standards, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of Fred Hutch and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with U.S. generally accepted accounting principles, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Fred Hutch's ability to continue as a going concern for one year after the date the consolidated financial statements are available to be issued.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and Government Auditing Standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion,



forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with GAAS and Government Auditing Standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Fred Hutch's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Fred Hutch's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated October 13, 2023 on our consideration of Fred Hutch's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of Fred Hutch's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Fred Hutch's internal control over financial reporting and compliance.

KPMG LLP

Seattle, Washington
October 13, 2023

FRED HUTCHINSON CANCER CENTER
Consolidated Statement of Financial Position

June 30, 2023

(in thousands)

Assets

Assets:

Cash and cash equivalents	\$	249,477
Patient accounts receivable, net		159,330
Grants and contracts receivable, net		44,389
Notes and pledges receivable, net		404,625
Investments		1,156,077
Land, buildings and equipment, net of accumulated depreciation		915,260
Right-of-use assets		210,283
Other assets		256,663
		256,663
Total assets	\$	3,396,104

Liabilities and Net Assets

Liabilities:

Accounts payable and accrued liabilities	\$	176,001
Other liabilities		93,313
Collaborative arrangement		428,824
Right-of-use lease liabilities		227,513
Long-term debt		1,086,339
Deferred credit on cashflow hedges		9,613
		9,613
Total liabilities		2,021,603

Net assets:

Without donor restrictions		737,448
With donor restrictions		637,053
		637,053
Total net assets		1,374,501
Total liabilities and net assets	\$	3,396,104

See accompanying Notes to Consolidated Financial Statements.

FRED HUTCHINSON CANCER CENTER

Consolidated Statement of Activities

Twelve months ended June 30, 2023

(in thousands)

	<u>Without donor restriction</u>	<u>With donor restriction</u>	<u>Total</u>
Revenues and other support:			
Patient service revenue, net	\$ 1,171,545	—	1,171,545
Research grants and contracts	587,481	—	587,481
Contributions	38,435	447,128	485,563
Investment income and realized gains, net	36,559	3,417	39,976
Clinical service fee revenue	20,468	—	20,468
Service and other income	40,118	—	40,118
Net assets release from restrictions	22,076	(22,076)	—
Total revenues	<u>1,916,682</u>	<u>428,469</u>	<u>2,345,151</u>
Operating expenses:			
Salaries, wages and benefits	664,362	—	664,362
Subawards	150,120	—	150,120
Purchased services	298,716	—	298,716
Collaborative arrangement	101,614	—	101,614
Supplies	516,655	—	516,655
Rent, utilities and maintenance	82,881	—	82,881
Interest, depreciation and amortization	94,509	—	94,509
Other	66,888	—	66,888
Total expenses	<u>1,975,745</u>	<u>—</u>	<u>1,975,745</u>
Change in net assets from operations	<u>(59,063)</u>	<u>428,469</u>	<u>369,406</u>
Other changes in net assets:			
Change in net unrealized fair value of investments	49,988	2,784	52,772
Change in net unrealized fair value of swap instruments	8,462	—	8,462
Other net asset changes	(1,727)	1,205	(522)
Total other changes in net assets	<u>56,723</u>	<u>3,989</u>	<u>60,712</u>
Total changes in net assets	<u>(2,340)</u>	<u>432,458</u>	<u>430,118</u>
Net assets balance at beginning of year	<u>739,788</u>	<u>204,595</u>	<u>944,383</u>
Net assets balance at end of year	<u>\$ 737,448</u>	<u>637,053</u>	<u>1,374,501</u>

See accompanying Notes to Consolidated Financial Statements.

FRED HUTCHINSON CANCER CENTER

Consolidated Statements of Cash Flows

For the period ended June 30, 2023

(In thousands)

Cash flows from operating activities:	
Change in net assets	\$ 430,118
Adjustments to reconcile change in net assets to net cash provided by (used in) operating activities:	
Depreciation and amortization	51,357
Change in noncash deferred revenue	(717)
Change in net unrealized fair value of investments	(52,772)
Change in net realized fair value of investments	(646)
Change in value of split interest agreements	(825)
Change in fair value of swap instruments	(8,462)
Loss on defeasance of debt	1,151
Noncash contributions	(38,834)
Restricted contributions	(18,025)
Changes in assets and liabilities:	
Grants and contracts receivable	27,678
Patient accounts receivable	(13,880)
Notes and pledges receivable	(394,516)
Other assets	13,665
Assets whose use is limited	73,930
Accounts payable and accrued liabilities	23,438
Change in right of use assets and lease liabilities	2,237
Net cash provided by operating activities	<u>94,897</u>
Cash flows from investing activities:	
Additions to land, buildings, equipment and rental property	(175,028)
Purchase of investments	(388,632)
Sale of investments	234,711
Net cash used in investing activities	<u>(328,949)</u>
Cash flows from financing activities:	
Additions to deferred financing costs	(118)
Repayment of debt	(3,958)
Contributions restricted for long-term investment	18,025
Net cash provided by financing activities	<u>13,949</u>
Net decrease in cash and cash equivalents	
	(220,103)
Cash, cash equivalents and restricted cash at beginning of year	
	<u>469,580</u>
Cash, cash equivalents and restricted cash at end of period	
	<u>\$ 249,477</u>
Supplemental cash flow disclosure:	
Interest paid	\$ 50,488
Capital expenditures in accounts payable	7,509

See accompanying Notes to Consolidated Financial Statements.

FRED HUTCHINSON CANCER CENTER
Notes to Consolidated Financial Statements
June 30, 2023
(In thousands)

(1) Organization

Fred Hutchinson Cancer Center (Fred Hutch) is a Washington not-for-profit corporation organized and operated exclusively for charitable, scientific, and educational purposes, within the meaning of Section 501(c)(3) of the Internal Revenue Code of 1986. It unites innovative research and compassionate care to prevent and eliminate cancer and infectious disease. It is driven by the urgency of our patients, the hope of our community and our passion for discovery to pursue scientific breakthroughs and healthier lives for every person in every community. Fred Hutch is designated by the National Cancer Institute as a comprehensive cancer research center.

Fred Hutch was formed in April 2022 when Fred Hutchinson Cancer Research Center (FHCRC), a cancer, infectious disease and biomedical research center, combined with the Seattle Cancer Care Alliance (SCCA), an integrated cancer care provider. Concurrent with the business combination, Fred Hutch entered into a Restructuring and Enhanced Collaboration Agreement (Collaboration Agreement) with University of Washington (UW) forming a clinically integrated adult oncology program spanning two institutions.

In support of its mission, Fred Hutch controls the following not-for-profit affiliates:

- The Hutchinson Centre Research Institute in Uganda Limited (HCRI-Ug) is a Uganda not-for-profit corporation. It is organized and operated for the purpose of researching, detecting, treating, and preventing infection-related cancers in Uganda and throughout the world. Fred Hutch is the sole member of HCRI-Ug. The income and property of HCRI-Ug are restricted to be used in meeting its organizational objectives. The net assets of HCRI-Ug of \$(16,859) as of June 30, 2023, are not considered pledged obligations under debt covenants.
- Hutchinson Centre Research Institute of South Africa (HCRISA) is a South Africa not-for-profit corporation. It is organized and operated for the purpose of promoting and conducting clinical, laboratory, and other research aimed at the prevention, early detection, diagnosis, and treatment of HIV/AIDS, Tuberculosis, and other infectious diseases and cancer in South Africa and throughout the world. Fred Hutch is the sole member of HCRISA. The income and property of HCRISA are restricted to be used in meeting its organizational objectives. The net assets of HCRISA of \$5,859 as of June 30, 2023, are not considered pledged assets under debt covenants.
- Seattle Vaccine Research Fund (SVRF), a Washington State not-for-profit corporation, is exempt from federal taxes under Section 501(c)(3). It is operated for the purpose of providing anti-retrovirals to eligible participants of HIV Trials Network. The net assets of SVRF of \$2,517 as of June 30, 2023, are not considered pledged assets under Fred Hutch's debt covenants.

(2) Summary of Significant Accounting Policies

(a) Basis of Presentation

The consolidated financial statements include the accounts of Fred Hutchinson Cancer Center and its controlled affiliates, collectively referred to as Fred Hutch. All significant intercompany balances and transactions between Fred Hutch and its controlled affiliates have been eliminated in consolidation.

FRED HUTCHINSON CANCER CENTER
Notes to Consolidated Financial Statements
June 30, 2023
(In thousands)

(b) Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

(c) Cash and Cash Equivalents

Fred Hutch maintains cash and cash equivalents on deposit at financial institutions, which at times exceed the limits insured by the Federal Deposit Insurance Corporation. This exposes Fred Hutch to insolvency risk if the financial institution becomes insolvent. Included in \$249,477 of cash and cash equivalents as of June 30, 2023 is \$9,939 of cash held by trustee.

(d) Assets Whose Use is Limited

Assets whose use is limited include net assets without donor restrictions designated by the Board of Directors (the Board) for future capital purpose over which the Board retains controls and may, at its direction, subsequently use for other purposes. Assets whose use is limited also include net assets with donor restrictions and funds held under the terms of Fred Hutch's trust indenture.

As of June 30, 2023, there were no assets whose use was limited.

(e) Supplies Inventory

Included in other assets on the Consolidated Statement of Financial Position is inventory consisting primarily of surgical, medical, and pharmaceutical supplies that is carried at the lower of cost (first-in, first-out method) or net realizable value.

(f) Land, Buildings, and Equipment

Land, buildings, and equipment acquisitions, improvements and replacements are recorded at cost. Buildings are depreciated on a straight-line basis over 40 to 45 years, while improvements and equipment are depreciated over 3 to 30 years, depending on the nature of the asset. The costs and related accumulated depreciation of land, buildings and equipment sold or retired are removed from the accounts and the resulting gain or loss is recognized.

Interest costs incurred on borrowed funds during the period of construction of capital assets are capitalized. Capitalization of interest ceases when the asset is placed in service.

Maintenance and repairs costs are expensed.

Land, buildings and equipment are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of the capital asset may not be recoverable.

Fred Hutch receives reimbursement for a portion of its buildings and equipment through direct and indirect cost reimbursement primarily from the federal government in connection with federal grants.

FRED HUTCHINSON CANCER CENTER
Notes to Consolidated Financial Statements
June 30, 2023
(In thousands)

(g) Leases

Fred Hutch is a lessee in noncancelable operating leases for research, clinic, and office space that expire over the next forty years and contain renewal options for periods ranging from two to fifty years. Fred Hutch has a finance lease for equipment as of June 30, 2023. Fred Hutch determines if an arrangement is or contains a lease at inception. A right-of-use (ROU) asset and a lease liability are recognized at the lease commencement date.

The lease liability represents Fred Hutch's obligation to make lease payments discounted to the present value of the unpaid lease payments at the commencement date of each lease.

The ROU asset represents Fred Hutch's right to use or control the use of a specified asset for a lease term and is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. The ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. These lease agreements do not contain any material residual value guarantees or material restrictive covenants. Leasehold improvements are capitalized at cost and amortized over the lesser of their expected useful life or the lease term.

Fred Hutch uses an incremental borrowing rate at the commencement date in determining the discounted present value of lease payments. The incremental borrowing rate is a hypothetical rate based on Fred Hutch's implicit credit rating.

Fred Hutch has elected not to recognize ROU assets and lease liabilities for lease terms of 12 months or less. Rent for these leases is expensed in the period incurred. Fred Hutch has elected not to apply the short-term lease recognition and measurement exemption for other classes of leased assets. Options for lease extensions that Fred Hutch is reasonably certain of exercising are considered in determining the lease term used to establish the right-of-use assets and lease liabilities.

Certain lease agreements contain both lease and non-lease components. Fred Hutch accounts for lease and non-lease components separately. Payments for the lease and non-lease (service) components are allocated based on estimated stand-alone values.

Fred Hutch also has leases that include variable payments based on measures such as level of use. These payments are expensed as incurred and reported in other operating expenses.

(h) Intangible Assets

Intangible assets are stated at fair value. All intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Intangible assets are amortized over the expected life of the asset.

In 2023 there were no impairment charges.

FRED HUTCHINSON CANCER CENTER

Notes to Consolidated Financial Statements

June 30, 2023

(In thousands)

(i) Patient Service Revenue

Fred Hutch treats contracts with similar characteristics as a portfolio for the patient service revenue stream as the revenue represents a large volume of similar contracts with similar classes of customers. Patient service revenue is comprised of two primary portfolios: clinical services and retail pharmacy operations.

Patient service revenue is reported at the estimated net realizable amount from patients, third party payors, and others for services rendered, including estimated retroactive adjustments under reimbursement agreements with third party payors. Retroactive agreements are accrued on an estimated basis in the period the related services are rendered and adjusted in future periods as final settlements are determined.

Clinical services are the services performed by physicians and other medical professionals to aid in the diagnosis and treatment of cancer. Fred Hutch satisfies clinical service performance obligations over time as services are rendered and thus, recognizes revenue for clinical services over time based on actual charges incurred. Fred Hutch believes that this method provides a useful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Fred Hutch bills patients and third-party payors several days after the services are performed and/or the patient is discharged from the facility.

The transaction price is based on standard charges for goods and services provided, reduced by contractual adjustments provided to third party payors and discounts provided to uninsured patients in accordance with Fred Hutch policy and implicit price concessions. Fred Hutch estimates the contractual adjustment for unpaid accounts based on contractual agreements, its discounts policies, and historical experience by class of patient. Fred Hutch analyzes the discounts on patient service revenue by portfolio of inpatient and outpatient clinical services and payor classification. Fred Hutch has sufficient historical information on these payor groups' collection rates and other information that allows Fred Hutch to analyze these statistics against the portfolio and conclude that the revenue for a given portfolio would not be materially different than if accounting for revenue on a contract-by-contract basis.

Retail pharmacy operations consist of sales of prescription and over the counter drugs. These revenues are recognized at a point in time, upon delivery of prescription and over the counter drugs to the patient. Fred Hutch sends billing information to the insurance companies at the time of prescription fulfillment. Patient responsible portion is billed at the time of prescription pick up.

Fred Hutch has elected to apply the optional exemption in FASB Accounting Standards Codification (ASC) 606-10-50-14a *Revenue from Contracts with Customers* as all Fred Hutch's performance obligations relate to contracts with a duration of less than one year. As such, Fred Hutch is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period as permitted in ASC 606-10-50-14a. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient clinical services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within one and a half weeks after the end of the reporting period.

FRED HUTCHINSON CANCER CENTER
Notes to Consolidated Financial Statements
June 30, 2023
(In thousands)

For patients that do not qualify for financial assistance, Fred Hutch recognizes that a portion of their patients will be unable or unwilling to pay for the services provided. Fred Hutch determines its estimate of implicit price concessions based on historical collection experience by primary payor class of patients. The implicit price concessions included in estimating the transaction price represent the difference between amounts billed to patients and the amounts Fred Hutch expects to collect based on its collection history with those patients.

Changes to the initial estimate of the transaction price are recorded as adjustments to patient service revenue in the period of the change while subsequent changes that are determined to be the result of an adverse change in the payor's ability to pay are recorded as bad debt expense.

(j) Charity

Fred Hutch provides care to patients who meet certain criteria under its financial assistance policy without charge or at amounts less than its established rates. Because Fred Hutch does not pursue collection of amounts determined to qualify as financial assistance, they are not reported as revenue. The estimated cost of financial assistance provided was approximately \$11,139 for the year ended June 30, 2023. The cost of financial assistance was calculated using a percentage of cost to charges, which was 46%. The number of financial assistance patients served was 2,769.

(k) Research Grants and Contracts Revenue

Fred Hutch recognizes revenue from grants and contracts on the research it performs. Grantors include both federal and nonfederal sponsors with approximately 81% of research revenue derived from federal agencies for the year ended June 30, 2023.

Research grants and contracts that represent exchange transactions are recognized as revenue as performance obligations are satisfied by achieving milestones or meeting performance obligations as disclosed in the agreement.

Research grants and contracts that represent non-exchange transactions are recognized as grant revenue in the period Fred Hutch meets the conditions for revenue recognition, namely when it incurs reimbursable program expenditures.

Fred Hutch has estimated that conditional contributions associated with grants and contracts that do not meet the revenue recognition criteria amount to \$269,268 as of June 30, 2023.

(l) Deferred Revenue and Grants and Contracts Receivable

Deferred revenue represents grant and contract funds received in advance for research to be performed by Fred Hutch in future periods. When Fred Hutch has received more funds than it has earned for a project, the difference is recorded as deferred revenue in other liabilities in the Consolidated Statement of Financial Position. When Fred Hutch has earned more revenue than project funds received, a receivable from the sponsors is recognized to the extent of remaining funding commitments in the grant and contracts receivable.

FRED HUTCHINSON CANCER CENTER
Notes to Consolidated Financial Statements
June 30, 2023
(In thousands)

(m) Contributions with Donor Restrictions

Unconditional promises to give cash and other assets are reported at fair value on the date the promise is received. The gifts are reported as donor restricted contributions if the donor stipulates either a time or purpose restriction. When a time restriction expires or a purpose restriction is fulfilled, the net assets with donor restrictions are reclassified as without donor restrictions and reported in the statement of activities as net assets released from restrictions. Contributions whose restrictions are met within the same year as received are reported as without donor restrictions in the accompanying consolidated financial statements.

Conditional promises to give are reported at fair value on the date the gift is received or when the conditions are met. Fred Hutch has estimated that conditional contributions with donor restrictions that do not meet revenue recognition criteria are \$225,000 as of June 30, 2023.

(n) Perpetual Trusts and Charitable Remainder Trusts

Fred Hutch is the beneficiary of irrevocable perpetual trusts and charitable remainder trusts for which Fred Hutch is not the trustee. These funds held in trust by others represent resources neither in the possession nor under the control of Fred Hutch and are administered by third party-trustees.

When Fred Hutch is notified of the existence of an irrevocable perpetual trust and can reasonably value its interest, Fred Hutch recognizes its beneficial interest in the outside trust at fair value as a contribution. The contribution is classified as an increase in net assets with donor restrictions based on restrictions placed by the donor. The changes in the fair value of the irrevocable perpetual trusts are reflected as investment changes in net assets with donor restrictions on the consolidated statement of activities.

When Fred Hutch is notified of an irrevocable charitable remainder trust for which it is not the trustee, Fred Hutch recognizes its beneficial interest in the outside trust as a contribution at fair value, which is measured as the present value of the estimated expected future benefits to be received. The contribution is classified as an increase in net assets with donor restrictions based on restrictions placed by the donor. Periodic adjustments are recorded to the beneficial interest to reflect changes in the fair value, life expectancy, and discount rate based on information from trustees. At June 30, 2023, there were \$3,787 of charitable remainder trusts for which Fred Hutch is not the trustee reflected as a receivable from trusts included in other assets in the accompanying consolidated statement of financial position.

(o) Foreign Currency Translation and Transaction Gains and Losses

The consolidated financial statements include foreign currency amounts attributable to foreign operations. The foreign currency amounts have been translated into U.S. dollars using year-end exchange rates for certain assets and liabilities, historical rates for net assets and average monthly rates for revenues and expenditures. Unrealized gains or losses arising from fluctuations in the year-end exchange rates of foreign currency denominated assets and liabilities are recorded as net asset adjustments from foreign currency translation, and gains or losses resulting from actual foreign exchange transactions are recorded in revenue and expenses in the consolidated statements of activities.

FRED HUTCHINSON CANCER CENTER
Notes to Consolidated Financial Statements
June 30, 2023
(In thousands)

(p) Net Assets with Donor Restrictions

Net assets with donor restrictions include amounts restricted for time or purpose and amounts that are restricted in perpetuity. Fred Hutch's net assets restricted in perpetuity consist of endowment funds and Fred Hutch's interest in perpetual trusts. Income earned on funds restricted in perpetuity is used for operations in accordance with the terms of each endowment fund and the Uniform Prudent Management of Institutional Funds Act (UPMIFA).

Net assets with donor restrictions are restricted for purposes designated by the donors for research and supportive patient care services. Net assets with donor restrictions that are perpetual in nature amounted to \$136,380 and amounts restricted for time or purpose amounted to \$500,585 as of June 30, 2023.

(q) Functional Expense Allocation Methodology

Fred Hutch's consolidated financial statements report certain categories of expenses that are attributable to more than one function. These expenses are allocated based on the appropriate metrics and consistently applied.

(r) Statement of Activities

The statement of activities describes the results of financial events included in the change in net assets. Contributions received are recorded either with or without donor restrictions. Investment income may be donor restricted or without donor restriction. Research grants and contracts revenue and related expenses incurred are without restriction. Changes in asset values resulting from fair value adjustments are shown as unrealized gains and losses under other changes in net assets. A total increase or decrease in net assets for each net asset grouping is shown to roll forward the beginning of the year balance to the end of the year balance.

(s) Commercialization Income

Fred Hutch actively works to develop scientific discoveries into new products and services. Revenue is generated from licensing agreements, partnerships, and royalty streams, and new businesses are reported within Service and Other Income on the consolidated statement of activities.

(t) Professional Liability Insurance

Fred Hutch has claims made—professional and general liability insurance for 2023. Fred Hutch has accrued an actuarial estimate of unreported instances and claims as of June 30, 2023, which is included in accounts payable and accrued liabilities.

(u) Federal Income Taxes

Fred Hutch has obtained a determination letter from the Internal Revenue Service that it is exempt from federal income taxes under Section 501(c)(3), except for unrelated business income. Unrelated business income typically is trade or business activity regularly carried on and is not related to furthering the exempt purpose of Fred Hutch. During 2023, Fred Hutch did not record any liability for uncertain tax benefits.

FRED HUTCHINSON CANCER CENTER
Notes to Consolidated Financial Statements
June 30, 2023
(In thousands)

(v) Recent Accounting Pronouncements

In March 2023, the FASB issued Accounting Standards Update (ASU) 2023-01, Common Control Arrangements. This ASU provides certain entities a practical expedient to use written terms and conditions for determining whether a lease exists and the accounting for the lease. The ASU also provides guidance related to accounting for leasehold improvements associated with common control leases. The ASU is effective for annual periods beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. Fred Hutch is evaluating the impact that ASU 2023-01 will have on its consolidated financial statements and will adopt the provisions upon the effective date.

(3) Due from Government Agencies

Fred Hutch incurs facilities and administrative (F&A) costs to support its government sponsored research activities. Sponsors are charged for these costs through an F&A cost rate, which is applied to modified total direct research costs. Both direct and F&A costs are recovered by Fred Hutch from research programs supported by federal and other grant revenue.

The fixed federal F&A rate for grant and contract supported programs is determined by prospective negotiation with the Department of Health and Human Services (DHHS) based on an estimate of the costs that will be incurred during the period to which the rate applies. Any difference between the costs recovered through the fixed F&A cost rate and actual F&A costs for a year are generally incorporated with the federal government through future rates. No estimated settlement was recorded as of June 30, 2023.

(4) Availability and Liquidity

Fred Hutch regularly monitors its ability to meet its cash flow requirements and operating needs. The availability of financial assets is primarily affected by management's designation and donor restrictions. The

FRED HUTCHINSON CANCER CENTER
Notes to Consolidated Financial Statements
June 30, 2023
(In thousands)

following financial assets on the statements of financial position are expected to be readily available for general expenditures within one year:

Financial assets:	
Cash and cash equivalents	\$ 249,477
Patient accounts receivable, net	159,330
Grants and contracts receivable, net	44,389
Notes and pledges receivable, net	404,625
Investments	1,156,077
Other financial assets	<u>222,710</u>
Total financial assets, at year-end	<u>2,236,608</u>
Less those unavailable for general expenditures within one year:	
Notes and pledges receivable, net	343,329
Investments	103,869
Other financial assets	<u>157,171</u>
Total unavailable for general expenditures within one year	<u>604,369</u>
Financial assets available for general expenditures within one year	<u>\$ 1,632,239</u>

Other assets on the Consolidated Statement of Financial Position are comprised of financial assets of \$222,710 and nonfinancial assets of \$33,953 as of June 30, 2023.

Financial assets not available for general expenditure within one year include amounts that will be paid beyond one year and donor restricted funds where release will occur beyond one year.

As part of Fred Hutch's liquidity management, it makes financial assets available based on forecasted liquidity requirements. Fred Hutch invests cash in excess of current requirements. In the event of unanticipated liquidity needs, Fred Hutch can increase liquidity.

(5) Investments

Investments are carried at fair value and include equity securities, debt securities, and alternative investments. GAAP provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below:

- Level 1 – Quoted prices (unadjusted) in active markets accessible at the measurement date for identical investments.

FRED HUTCHINSON CANCER CENTER

Notes to Consolidated Financial Statements

June 30, 2023

(In thousands)

- Level 2 – Inputs based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in inactive markets, data other than quoted prices that are observable for the asset or liability, and data that are derived principally from or corroborated by observable market data by correlation or other means.
- Level 3 – Inputs that are derived principally from or corroborated by unobservable market data by correlation or other means.

The level in the fair value hierarchy within which a fair value measurement in its entirety falls is based on the lowest level input that is significant to the fair value measurement in its entirety.

(a) Fair Value Calculation Methodology

The following methods and assumptions were used to estimate the fair value of each class of financial instruments for which it is practicable to estimate that value:

Investments and trusts – Investments in equity and debt securities, beneficial interest in charitable remainder trusts and perpetual trusts are measured at fair value based on quoted market prices, if available, or estimated using quoted market prices for similar securities. Alternative investments are measured at fair value based on each fund's net asset value (NAV) as a practical expedient. Other equity securities, which are shares held in a nonpublic entity, are measured at fair value based on management's valuation model. Management's model utilizes data and assumptions that are not observable to market participants.

Long-term debt – The carrying amount of long-term debt with variable interest rates approximates fair value because interest rates are adjusted either daily or weekly for the variable rate demand bonds. The carrying amount of the fixed rate debt is calculated based upon the net present value of the future cash outflows of the associated fixed rate debt discounted at the interest rates in effect as of June 30, 2023.

Cash flow hedges – The carrying amounts of the interest rate swaps are at estimated fair values based on the net present value of the associated variable cash flows, adjusted for Fred Hutch's and the respective counterparty's nonperformance risk.

(b) Fair Value Hierarchy

In accordance with GAAP, certain investments that were measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the line items presented in the statements of financial position.

FRED HUTCHINSON CANCER CENTER
Notes to Consolidated Financial Statements
June 30, 2023
(In thousands)

The following tables present assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2023:

	<u>June 30, 2023</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>
Investments measured by fair value level:				
US Treasury notes and bills	\$ 71,700	71,700	—	—
Global equity securities and funds	529,259	526,892	2,367	—
Governments, mortgage, and corporate debt funds	440,910	262,560	178,350	—
Commodity investment and funds	9,453	9,453	—	—
Other equity securities	3,358	—	—	3,358
Total investments by fair value level	<u>\$ 1,054,680</u>	<u>870,605</u>	<u>180,717</u>	<u>3,358</u>
Investments measured using NAV:				
Global equity securities	51,913			
Private equity and venture capital funds	18,795			
Directional hedge securities	30,689			
Total investments measured using NAV	<u>101,397</u>			
Total investments	<u>\$ 1,156,077</u>			

	<u>June 30, 2023</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>
Investments measured by fair value level:				
Assets:				
Beneficial interest in charitable remainder trusts	\$ 3,434	—	—	3,434
Beneficial interest in perpetual trusts	33,285	—	—	33,285
Liabilities:				
Deferred credit on cash flow hedges	\$ (9,613)	—	(9,613)	—

FRED HUTCHINSON CANCER CENTER
Notes to Consolidated Financial Statements
June 30, 2023
(In thousands)

There was no material activity in Level 3 investments during the current year. No new charitable remainder trusts were added during the year ended June 30, 2023.

Fred Hutch's interests in certain non-readily marketable alternative investments, such as hedge funds and private equity limited partnerships, are stated at fair value based on NAV estimates used as a practical expedient reported to Fred Hutch by investment fund managers. The valuation method for investments measured using NAV per share (or its equivalent) is presented in the following table.

	<u>June 30, 2023</u>	<u>Redemption or liquidation</u>	<u>Days notice</u>	<u>Unfunded commitment</u>
Global equity securities	\$ 51,913	Monthly	30	\$ N/A
Private equity and venture capital funds	18,795	N/A	N/A	11,539
Directional hedge securities	<u>30,689</u>	Every 2 years	30 – 184	N/A
Total investments measured using NAV	<u>\$ 101,397</u>			

Global equity securities: This investment category includes public equity investments in separately managed accounts, log-only comingled funds, and passive market indices. Fair values have been determined using the NAV per share of the investments. All of the investments in this category can be redeemed within a year.

Private equity and venture capital funds – This category includes real estate, buyout, venture, and special situation funds. Fair values have been determined using the NAV per share (or its equivalent) of the ownership interest in partners' capital. These investments can never be redeemed with the funds. Distributions from each fund will be received as the underlying investments are liquidated. It is expected that the majority of the underlying assets of the funds will be liquidated over the next 15 years.

Directional hedge securities – The categories include public equity investments in separately managed accounts, long and short comingled funds. Fair values have been determined using the NAV per share (or its equivalent) of the ownership in the partners' capital or the investment fund. Approximately 93% of the investments in this category can be redeemed within next year and 7% can be redeemed in two years.

Fred Hutch's investments contain endowment funds with donor restrictions for research and other related purposes. Net assets associated with endowment funds are classified and reported based on the existence or absence of donor imposed restrictions. Fred Hutch's board designated investments include funds designated to function as endowments and funds designated for the clinic expansion. The Board of Directors may also elect to remove designations on funds previously designated.

FRED HUTCHINSON CANCER CENTER
Notes to Consolidated Financial Statements
June 30, 2023
(In thousands)

(c) Components of Investment Income for the year ended June 30 are as follows:

Investment income:	
Interest and dividend income	\$ 40,572
Net realized gains	645
	41,217
Less investment management fees	(1,241)
Total investment income	\$ 39,976

(6) Endowments

(a) Return Objectives and Risk Parameters

Fred Hutch has adopted investment and spending policies for its endowment that aim to provide resources to its programs. The endowment includes donor restricted-funds as well as board designated-investments. Under this policy, as approved by the finance committee of Fred Hutch's Board of Directors, the primary objective of the investment of the endowment is to provide a rate of total return that exceeds the rate of inflation (as represented by the Consumer Price Index All-Urban Consumers) plus 5% over the long term. Fred Hutch defines the long term as five years and more. Consistent returns are to be emphasized over individual year results. The endowment should experience risk (volatility and variability of return) no greater than that of the market. Fred Hutch defines the market as the portfolio's asset allocation policy applied to the Russell 3000 Index, the Morgan Stanley Capital Europe, Australia, Far East (EAFE) Index or its equivalent, and the Bloomberg Barclays U.S. Aggregate Bond Index.

(b) Strategies Employed for Achieving Objectives

Fred Hutch relies on a total return strategy in which investment returns are achieved through both capital appreciation and current income to achieve its long-term-rate of return objectives. Fred Hutch utilizes an efficient frontier approach to establish the appropriate asset allocation balancing long-term-return objectives within prudent risk constraints. The finance committee of Fred Hutch's Board of Directors reviews Fred Hutch's asset allocation at least once a year.

(c) Spending Policies and How the Investment Objectives Relate to Spending Policies

Fred Hutch's spending policy for individual endowment funds is to appropriate for distribution each year 5% of the endowment fund's average fair value over the prior three years, provided that the fair value of the endowment fund exceeds the corpus. Certain board designated-funds held for future capital and debt obligations do not make distributions. For the remaining endowment funds, Fred Hutch appropriates distributions to support its programs.

(d) Funds with Deficiencies

Unless otherwise agreed with the donor, Fred Hutch's policy has been to maintain the value of the original corpus of each individual donor restricted-endowment fund. From time to time, the fair value of

FRED HUTCHINSON CANCER CENTER
Notes to Consolidated Financial Statements
June 30, 2023
(In thousands)

assets in such endowment funds may fall below this level or such other level as may have been agreed to by the donor or required by law. Losses on donor restricted endowment funds reduce net assets with donor restrictions. As of June 30, 2023, there were seven funds with a fair market value below the original corpus value.

(e) Endowment Allocation and Activity

The following tables show the net asset composition of Fred Hutch's endowment funds by type of fund as of June 30, 2023:

	<u>Without donor restriction</u>	<u>With donor restriction</u>	<u>Total</u>
Donor-restricted endowment funds	\$ —	110,275	110,275
Board designated endowment funds	436,775	—	436,775
	<u>\$ 436,775</u>	<u>110,275</u>	<u>547,050</u>

The following tables show the activity that has occurred within the endowment net asset accounts for the year ended June 30, 2023:

	<u>Without donor restrictions</u>	<u>With donor restrictions</u>	<u>Total</u>
Endowment net assets, beginning of year	\$ 400,424	102,032	502,456
Investment return:			
Investment income	8,798	1,816	10,614
Net realized gain	604	1,955	2,559
Net appreciation – unrealized	29,054	2,784	31,838
Total investment return	38,456	6,555	45,011
Contributions	—	6,595	6,595
Distributions	—	(282)	(282)
Board transfers In/(Out)	460	(451)	9
Appropriation of endowment assets for expenditure	(2,565)	(4,174)	(6,739)
Endowment net assets, end of year	<u>\$ 436,775</u>	<u>110,275</u>	<u>547,050</u>

Contributions to the endowment are only added when cash is received; pledges are recorded outside of the endowment net assets until collected.

FRED HUTCHINSON CANCER CENTER
Notes to Consolidated Financial Statements
June 30, 2023
(In thousands)

(7) Land, Buildings, and Equipment

Summaries of land, buildings and equipment at cost as of June 30 are as follows:

Land	\$	142,661
Buildings		979,084
Equipment		298,828
Construction in progress		35,115
		1,455,688
Less accumulated depreciation		(540,428)
Total land, buildings and equipment, net of accumulated depreciation	\$	915,260

For the year ended June 30, 2023 capitalized interest and depreciation expense amounted to \$22,426 and \$52,554, respectively.

(8) Notes and Pledges Receivable

Pledges receivable are unconditional donor promises to give and are initially recorded at fair value by discounting the expected future pledge payments.

The primary unobservable input used in the fair value measurement of pledges receivable is the discount rate. Significant fluctuations in the discount rate could result in a material change. The discount rate is based on the Treasury Constant Maturity rate, and is revised at each measurement date to reflect current market conditions.

FRED HUTCHINSON CANCER CENTER
Notes to Consolidated Financial Statements
June 30, 2023
(In thousands)

Unconditional pledges are expected to be received in the following periods:

Payments through June 30,		
2024	\$	61,296
2025		59,529
2026		58,575
2027		59,045
2028		58,515
Thereafter		<u>175,715</u>
		472,675
Less discount, net		<u>(70,326)</u>
Total pledges receivable, net		402,349
Add notes receivable		<u>2,276</u>
Total notes and pledges receivable, net	\$	<u><u>404,625</u></u>

(9) Collaboration Agreement

Under the terms of the Collaboration Agreement, University of Washington Medicine (UWM) relinquished its membership interest in the SCCA, and UW and Fred Hutch restructured their cancer programs into a single clinically integrated adult oncology program that unites innovative research and compassionate care to prevent and eliminate cancer and infectious disease. Under a management agreement, Fred Hutch provides management services to participating UWM oncology programs.

The Collaboration Agreement includes a Financial Alignment Plan (FAP). The FAP prescribes the methodologies to allocate clinical resources and provides for a perpetual flow of funds between Fred Hutch and UWM to support the integrated program. The flow of funds is expected to be predominantly from Fred Hutch to UWM, but under certain conditions payments from UWM to Fred Hutch may be required. The FAP was accounted for in accordance with *Collaborative Arrangements (Topic 808)* with a recorded long-term liability of \$428,824. A Collaborative Arrangement expense of \$101,614 was accrued for the year ended June 30, 2023.

UWM and Fred Hutch will determine the final settlement of the annual FAP calculations 180 days after fiscal year-end. Upon finalization and mutual approval, a final payment will be made for that fiscal year. As of June 30, 2023 Fred Hutch accrued \$27,385 of Collaboration Expense payable to UWM pending final settlement.

FRED HUTCHINSON CANCER CENTER
Notes to Consolidated Financial Statements
June 30, 2023
(In thousands)

(10) Long-Term Debt

Summaries of long-term debt as of June 30 are as follows:

Washington Health Care Facilities Authority Revenue Bonds, Series 2022C, due in varying amounts through 2052 plus interest at a variable interest rate	\$ 55,000
Washington Health Care Facilities Authority Revenue Bonds, Series 2022D, due in varying amounts through 2034 plus interest at a fixed interest rate	103,545
Washington Health Care Facilities Authority Revenue Bonds, Series 2022E, due in varying amounts through 2052 plus interest at a variable interest rate	125,000
Taxable Bonds, Series 2022, due in 2052 plus interest at a fixed interest rate	300,000
Washington Health Care Facilities Authority Revenue Bonds, Series 2021, (SCCA), due in varying amounts through 2048 plus interest at fixed rates, net of unamortized bond premium of \$5,567	41,782
Washington Health Care Facilities Authority Revenue Bonds, Series 2020, (SCCA), due in varying amounts through 2055 plus interest at fixed rates, net of unamortized bond premium of \$39,700	272,625
Taxable Bonds, Series 2020, (FHCRC) due in varying amounts through 2050 at a fixed interest rate	121,225
Washington Health Care Facilities Authority Revenue Bonds, Series 2014, (SCCA), due in varying amounts through 2055 plus interest at fixed rates, net of unamortized bond premium of \$3,363	68,413
Notes payable, net of unamortized discount \$380	<u>5,688</u>
	1,093,278
Less deferred financing costs	<u>(6,939)</u>
Long-term debt, net	<u>\$ 1,086,339</u>

All of the Revenue Bonds above are subject to the terms of Fred Hutch's Master Trust Indenture which defines the members of the Obligated Group for the long-term debt, establishes a collateral pledge on the gross receivables of the Obligated Group and provides covenants, including a requirement to maintain a debt service coverage ratio of 1.10 to 1.00.

On June 30, 2022, Fred Hutch issued \$283,545 Series 2022 C, D, E, and \$300,000 Taxable Bonds Series 2022. The proceeds were used to refinance a taxable bridge loan, finance general corporate purposes and pay for the costs of the Series 2017C, D, E Bonds and the Taxable Bonds Series 2022. The Series 2022D Bonds have a fixed interest rate of 3.34% while the Taxable Bonds Series 2022 have a fixed interest rate of 4.97%. The Series 2022C Bonds and Series 2022E Bonds have a variable interest rate.

In fiscal year 2021, Fred Hutch borrowed the proceeds of the Washington Health Care Facility Authority's \$37,605 Revenue Bonds, Series 2021 (the 2021 Bonds). The bonds are issued for the purpose of providing the funds necessary, together with certain other moneys to, (1) finance, refinance, or reimburse a portion of

FRED HUTCHINSON CANCER CENTER
Notes to Consolidated Financial Statements
June 30, 2023
(In thousands)

the costs of acquisition of Seattle Proton Holdings, construction, remodeling, renovating, and equipping of certain health care facilities owned and operated by Fred Hutch, (2) redeem all of the outstanding Wisconsin Public Finance Authority Revenue Bonds, Series 2018A (Seattle Proton Center, LLC) acquired in the Business combination, and (3) pay certain costs incurred in the issuance and sale of the 2021 Bonds. The 2021 Bonds have fixed interest rates ranging from 3.00% to 5.00%

In fiscal year 2021, Fred Hutch borrowed the proceeds of the Washington Health Care Facility Authority's \$232,925 Revenue Bonds, Series 2020 (the 2020 Bonds). The Bonds are issued for the purpose of providing the funds necessary to (1) finance, refinance, or reimburse a portion of the costs of acquisition, construction, remodeling, renovating and equipping certain health care facilities owned and operated by Fred Hutch (2) advance refund and defease all of the Washington Health Care Facilities Authority Revenue Bonds, Series 2010 (Seattle Cancer Care Alliance) previously owned, (3) fund capitalized interest and (4) pay certain costs incurred in the issuance costs of the 2020 bonds. The 2020 bonds have fixed interest rates ranging from 4.00% to 5.00%.

In fiscal year 2020, Fred Hutch issued taxable bonds (the 2020 Taxable Bonds) with a par amount of \$121,225 and a maturity date of January 1, 2050. The 2020 Taxable Bonds are in varying amounts with a fixed average coupon rate of 3.95%. The proceeds were used to defease the Washington Health Care Facilities Authority Revenue Bonds, Series 2011A (Fred Hutchinson Cancer Research Center). The 2020 Taxable Bonds were issued under a public bond placement.

In fiscal year 2015, Fred Hutch borrowed the proceeds of the Washington Health Care Facility Authority's \$86,950 Revenue Bonds, Series 2014 (the 2014 Bonds). The 2014 Bonds are issued for the purpose of providing the funds necessary to advance refund and defease all the Washington Health Care Facility Authority, Revenue Bonds, Series 2008 (Seattle Cancer Care Alliance), and pay certain costs in connection with the issuance of the 2014 Bonds. The 2014 Bonds have fixed interest rates ranging from 4.00% to 5.00%.

As a result of the business combination with Seattle Proton Holdings and SCCA in February 2021, Fred Hutch assumed two notes payable. The remaining principal and accrued interest balances totaling \$5,688 and \$160 respectively, on June 30, 2023. The terms of the notes state the unsecured debt accrues interest at a rate of 5% per year. Future payments of principal and interest on these notes will be made only from excess cash generated by the proton facility as defined in the agreements, if certain financial ratios have been met, and the aggregate amount of all such payments do not exceed \$836K for any fiscal year.

FRED HUTCHINSON CANCER CENTER
Notes to Consolidated Financial Statements
June 30, 2023
(In thousands)

The following schedule shows future long-term maturities by year:

2024	\$	13,732
2025		14,250
2026		14,784
2027		15,332
2028		15,892
Thereafter		971,038
		1,045,028
Plus unamortized net premiums		48,250
	\$	1,093,278

(11) Retirement Plan

Fred Hutch has a 403(b) defined contribution plan for its salaried employees. Employees are generally eligible after one year of service. Fred Hutch contributes 7% of each employee’s compensation up to the Social Security wage base limit and 12% on compensation above that limit. For certain management employees, Fred Hutch contributes 10% of compensation up to the Social Security wage base limit and 15% above the limit.

Retirement plan contributions for the year ended June 30, 2023, were \$37,143.

(12) Annuities

Fred Hutch administers gift annuities for which it makes periodic distributions to the annuitants. When contributed assets are initially received, the assets are recorded at fair value within the investments balance, and contribution revenue is recorded equal to the value of the contributed assets received less the annuity liability. The present value of the annuity liability totaled \$2,072 on June 30, 2023. The reserve fund requirement as determined by actuarial means was \$2,693 on June 30, 2023. The liability is revalued annually based upon actuarially computed present values and recorded in accrued liabilities. Present values are based on life expectancy and discount rates. Fred Hutch maintains segregated funds that exceed the actuarial value of the annuity liability as required by law.

(13) Leases

Fred Hutch has various operating and one finance lease for clinical, office, and equipment.

Payments due under the lease contracts include fixed payments plus market rate adjustments. The leases do not include any variable lease costs.

FRED HUTCHINSON CANCER CENTER
Notes to Consolidated Financial Statements
June 30, 2023
(In thousands)

The components of the lease cost for the year ended June 30, 2023 were as follows:

Fixed lease costs	\$	28,063
Variable lease costs		<u>5,125</u>
Total lease costs	\$	<u><u>33,188</u></u>

Weighted average remaining lease term and discount rates are as of June 30:

Weighted average remaining lease term in years:		
Operating lease		16.10
Finance lease		3.14
Weighted average discount rate:		
Operating lease		3.21 %
Finance lease		3.76

Supplemental information related to leases are as follows on June 30:

	Statement of position classification	2023
Assets:		
Operating right-of-use	Right-of-use assets	\$ 206,918
Finance right-of-use	Right-of-use assets	<u>3,365</u>
Total leased assets		<u><u>\$ 210,283</u></u>
Liabilities:		
Operating	Right-of-use lease liabilities	\$ 224,148
Finance	Right-of-use lease liabilities	<u>3,365</u>
Total leased liabilities		<u><u>\$ 227,513</u></u>

The cash paid for amounts included in lease costs was \$22,532 for operating leases and \$1,158 for financing leases during the year ended June 30, 2023.

FRED HUTCHINSON CANCER CENTER
Notes to Consolidated Financial Statements
June 30, 2023
(In thousands)

Maturities of lease liabilities under noncancelable leases as of June 30, 2023, are as follows:

	<u>Operating</u>	<u>Finance</u>	<u>Total</u>
2024	\$ 20,290	1,158	21,448
2025	19,652	1,158	20,810
2026	19,721	1,158	20,879
2027	20,160	1,158	21,318
2028	18,398	95	18,493
Thereafter	<u>196,393</u>	<u>—</u>	<u>196,393</u>
Total undiscounted cash flows	294,614	4,727	299,341
Less imputed Interest	<u>(70,466)</u>	<u>(1,362)</u>	<u>(71,828)</u>
Present value of lease liabilities	<u>\$ 224,148</u>	<u>3,365</u>	<u>227,513</u>

There are no real estate obligations for leases signed but not yet commenced as of June 30, 2023.

(14) Contingencies

(a) *Litigation and Compliance with Laws and Regulations*

Fred Hutch is subject to litigation and regulatory investigations arising in the normal course of its business. After consultation with legal counsel, management estimates that these matters will be resolved without material adverse effects on Fred Hutch's future financial position or results from operations.

The research industry is subject to numerous federal, state, and local laws and regulations. Some of these laws govern licensure, accreditation, and government program participation requirements. Government agencies are actively conducting investigations concerning possible violations of these statutes and regulations by research facilities. Violations of these laws and regulations could result in expulsion from government programs, together with the imposition of significant fines and penalties. Compliance with laws and regulations is subject to future government review and interpretation of such laws and regulations as well as regulatory actions unknown or unasserted at this time.

The healthcare industry is subject to numerous laws and regulations of federal, state, and local governments. These laws and regulations include, but are not limited to, matters such as licensure, accreditation, governmental healthcare program participation requirements, reimbursement for patient services, and Medicare and Medicaid fraud and abuse. Government agencies are actively conducting investigations concerning possible violations of fraud and abuse statutes and regulations by healthcare providers. Violations of these laws and regulations could result in expulsion from government healthcare programs, together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. Through its compliance program, Fred Hutch maintains an effective and safe program for reporting and addressing potential regulatory concerns. Compliance with such laws and regulations can be subject to future government review and interpretation as well as regulatory actions known or unasserted at this time.

FRED HUTCHINSON CANCER CENTER
Notes to Consolidated Financial Statements
June 30, 2023
(In thousands)

(b) Contingent Liability

Fred Hutch received federal grant funding for a portion of the construction of its South Lake Union Campus. Because Fred Hutch received federal grant funding for a portion of its campus, the government retains an interest in the net proceeds received if portions of the campus are sold. No liability is recorded related to this interest. Management has determined the probability of this transaction occurring is remote and the value of the interest is unmeasurable.

(15) Functional Expenses

Fred Hutch provides clinical healthcare and research services. The following tables present expenses by both their nature and function for the year ended June 30, 2023:

	<u>Program services clinical</u>	<u>Program services research</u>	<u>Management and general</u>	<u>Fundraising</u>	<u>Grand Total</u>
Salaries, wages and benefits	\$ 207,092	346,107	98,560	12,603	664,362
Subawards	—	150,120	—	—	150,120
Purchased services	191,576	61,405	42,110	3,625	298,716
Collaborative arrangement	—	—	101,614	—	101,614
Supplies	467,460	44,631	4,478	86	516,655
Rent, utilities and maintenance	36,540	20,406	25,790	145	82,881
Interest, depreciation and amortization	25,340	57,558	11,366	245	94,509
Other	10,662	29,343	17,976	8,907	66,888
Total operating expenses	<u>\$ 938,670</u>	<u>709,570</u>	<u>301,894</u>	<u>25,611</u>	<u>1,975,745</u>

(16) Related Party–Transactions

Fred Hutch purchases services and products from its related parties. By leveraging the existing infrastructure of its related parties, Fred Hutch has financially benefited from avoiding duplication of overhead and services. Each year Fred Hutch negotiates services and costs with its related parties. Purchased goods and services support the operation of the 20–bed licensed hospital and its ambulatory cancer care services. Purchases include physician and other clinical and non-clinical labor, certain support functions such as information technology, facility and equipment rental, pharmaceutical and other medical supplies, data collection and analysis, and license rights to related party organizations' names.

Fred Hutch also sells goods and services to its related parties including programmatic direction for cancer services, other clinical and non-clinical labor, and facility rental.

FRED HUTCHINSON CANCER CENTER
Notes to Consolidated Financial Statements
June 30, 2023
(In thousands)

The following table summarizes, by related party, the impact of these transactions to the accompanying consolidated statements of activities and financial position.

	<u>Service and other income</u>	<u>Research grants and contracts</u>	<u>Contributions</u>	<u>Interest income</u>	<u>Total</u>	
UW	\$ 15,944	11,509	(193)	6,551	33,811	
	<u>Purchased services</u>	<u>Subawards</u>	<u>Supplies</u>	<u>Lease expense</u>	<u>Other</u>	<u>Total</u>
UW	\$ 154,045	30,400	10,015	732	6,788	201,980

Amounts due from or due to related parties included in other assets and accounts payable and accrued expenses for the various transactions described above are as follows on June 30:

	<u>Due from related party</u>	<u>Due to related party</u>
UW	\$ 4,904	18,094

(17) Service and Other Income

Service and other income includes income from noncore sources, including service agreements, commercialization, related party–transactions, professional services, core resources, rent, parking, and similar activities. Fred Hutch had \$40,118 of service and other income for the year ended June 30, 2023.

(18) Net Patient Service Revenue

Fred Hutch has agreements with third-party payors that provide payments to Fred Hutch at amounts different from its established rates. Patient services revenues were billed to the following payors for the year ended June 30, 2023:

Commercial	\$ 738,201
Medicare	391,052
Medicaid	42,119
Self-pay and other	<u>173</u>
Total patient services revenue	<u>\$ 1,171,545</u>

For the year ended June 30, 2023, revenue recognized from performance obligations related to prior periods (for example, due to changes in transaction price) was insignificant.

FRED HUTCHINSON CANCER CENTER
Notes to Consolidated Financial Statements
June 30, 2023
(In thousands)

A summary of the payment arrangements with major third-party payors is as follows:

(a) Commercial

Fred Hutch negotiates contracts for reimbursement of care provided to patients with commercial third-party insurance payors.

For certain commercial payors, Fred Hutch has negotiated a single payment (case rate) for a defined period of care (case rate period) related to providing a bone marrow or stem cell transplant. All of Fred Hutch's case rate contracts specify a minimum and maximum payment calculation based on a review of actual gross charges provided during the case rate period. In addition to the case rate payments, the case rate contracts also specify negotiated fee-for-service rates for services performed outside of the case rate period. Case rate contracts extend to Fred Hutch related parties. Fred Hutch serves as the collection agent for the case rate payments. All case rate payments are remitted to Fred Hutch, which in turn remits payments to each respective related party for its proportionate share of services rendered. Any liability to related parties has been accrued in accounts payable and accrued expenses on June 30, 2023.

(b) Medicare

Medicare pays for inpatient hospital services under the prospective payment system (PPS) unless the provider is statutorily exempt from PPS (Exempt Hospital). PPS hospitals are paid a predetermined flat rate for inpatient care that is based on the patient's diagnosis at discharge while Exempt Hospitals are paid based on the "reasonable cost" of the services provided subject to an annual rate of increase limit. Exempt Hospitals receive an interim payment based on a percentage of charges submitted that is adjusted based on the filed cost report. Certain types of cancer hospitals are currently included among the Exempt Hospitals. Fred Hutch's inpatient facility is recognized by Medicare as an Exempt Hospital.

Medicare has historically paid for outpatient services on the basis of the cost of or a portion of the cost of providing the services. The Balanced Budget Act of 1997 required a phased in prospective payment system for outpatient services (OP PPS). The Center's for Medicare and Medicaid Services (CMS), an agency of the United States Department of Health and Human Services, issued regulations implementing OP PPS, which became effective as of August 1, 2000. Before the effective date of OP PPS, the Balanced Budget Refinement Act of 1999 established a "hold harmless" provision for cancer hospitals ensuring that they would be supplemented for certain covered services incurred under OP PPS. Under the hold harmless provision, if the amount of payment the cancer hospital would receive under OP PPS is less than what it would have received before OP PPS' implementation, the amount of payment due to the cancer hospital will be increased by the amount of such difference. As an Exempt Hospital, Fred Hutch qualifies for payment under the hold harmless provision.

The Budget Control Act of 2011 requires automatic spending reductions beginning April 1, 2013 to reduce the federal deficit, including Medicare spending reductions of up to 2% for a fiscal year, with a uniform percentage reduction across all Medicare programs. In 2013, the CMS notified Fred Hutch that Medicare fee-for-service claims with dates of service or dates of discharge on or after April 1, 2013 will incur a 2% reduction in Medicare payments.

FRED HUTCHINSON CANCER CENTER
Notes to Consolidated Financial Statements
June 30, 2023
(In thousands)

Settlements with third-party payors for retroactive adjustments due to audits, review or investigations are considered variable consideration and are included in the determination of estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and Fred Hutch's historic settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews, and investigations. Adjustments from finalizations of prior-year cost reports and other third-party settlement estimates resulted in an increase of net patient service revenues of approximately \$6,759 in 2023.

(c) Medicaid

Fred Hutch is paid for services provided to Medicaid patients under the state's fee schedule, which is based on a modification of Medicare's prospective payment systems for inpatient and outpatient care. In 2009, the State of Washington enacted a safety net assessment program involving Washington State hospitals to increase funding from other sources and obtain additional federal funds to support increased payments to providers for Medicaid services.

(d) Self-Pay & Other Insurers

Self-pay patients are those who do not qualify for government program payments, such as Medicare and Medicaid, do not have private insurance, and therefore are responsible for their own medical bills. Despite comprising a smaller percent of Fred Hutch's patient service revenues, the risk of collectability is higher with self-pay accounts. Any increases in uninsured individuals or changes to the payor mix could increase amounts due from individuals.

Other Insurers are patients whose funding stems from TRICARE and other insurers such as workers' compensation. TRICARE is the Department of Defense's health care program for members of the armed forces. For inpatient clinical services, TRICARE reimburses Fred Hutch based on a Diagnosis Related Group (DRG) system modeled on the Medicare inpatient PPS. For outpatient clinical services, TRICARE reimburses Fred Hutch based on a PPS that is similar to that utilized for services provided to Medicare beneficiaries.

FRED HUTCHINSON CANCER CENTER
Notes to Consolidated Financial Statements
June 30, 2023
(In thousands)

(19) Concentration of Credit Risk

Fred Hutch grants credit without collateral to its patients, most of whom are insured under third-party payor agreements. Percentage of outstanding patient accounts receivable by third-party-payor and patients are as follows on June 30, 2023:

Patient accounts receivable:	
Commercial	50 %
Medicare	35
Medicaid	12
Self-pay and other	3
Total	100 %

(20) Accounting for Derivative Instruments and Hedging Activities

Accounting principles require that every derivative instrument (including certain derivative instruments embedded in other contracts) be recorded on the statement of financial position as either an asset or liability measured at its fair value.

(a) Interest Rate Swaps

Fred Hutch has entered into two interest rate swap agreements to mitigate the risks associated with variable rate bond issues. This agreement has been amended in December 2017. The duration of the swaps extended to 2042 to match up the duration of the existing underlying variable rate bonds. The first swap has a notional amount of \$56,577. The interest rate paid by Fred Hutch is fixed at 3.60% while the counterparty pays Fred Hutch 67% of an indexed rate. The second swap has a notional value of \$52,723. The interest rate paid by Fred Hutch is fixed at 3.53% while the counterparty pays Fred Hutch 89% of an indexed rate.

The fair value is the estimated amount the counterparties would receive or pay to terminate the swap agreements at the reporting date based on current interest rates and the current creditworthiness of the swap counterparties. The fair value of the swaps, recorded as deferred credits on cash flow hedges, was \$9,613 on June 30, 2023.

(b) Collateral Posted with Swap Counterparty

The swap agreements contain terms that require Fred Hutch to post collateral with the counterparty if certain conditions are met, including when the fair value amount to terminate the swaps exceeds \$40,000 as of June 30, 2023. No collateral amounts were required to be posted as of June 30, 2023.

FRED HUTCHINSON CANCER CENTER
Notes to Consolidated Financial Statements
June 30, 2023
(In thousands)

(c) *Currency hedge activity*

Fred Hutch purchases forward contracts for South African Rand (ZAR) currency. This allows Fred Hutch to mitigate currency risk related to HCRISA research activities in South Africa. Outstanding forward contracts that obligate Fred Hutch to purchase ZAR on June 30, 2023 was R120,000 (\$6,455 USD).

(21) Subsequent Events

Fred Hutch has evaluated subsequent events through October 13, 2023 the date the consolidated financial statements were issued, and has included all necessary adjustments and disclosures.



KPMG LLP
Suite 2800
401 Union Street
Seattle, WA 98101

Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With *Government Auditing Standards*

The Board of Directors
Fred Hutchinson Cancer Center:

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated financial statements of Fred Hutchinson Cancer Center (Fred Hutch), which comprise Fred Hutch's consolidated statement of financial position as of June 30, 2023, and the related consolidated statement of activities and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated October 13, 2023.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered Fred Hutch's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of Fred Hutch's internal control. Accordingly, we do not express an opinion on the effectiveness of Fred Hutch's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether Fred Hutch's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.



Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

KPMG LLP

Seattle, Washington
October 13, 2023



KPMG LLP
Suite 2800
401 Union Street
Seattle, WA 98101

Independent Auditors' Report on Compliance for Each Major Federal Program; Report on Internal Control Over Compliance; and Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

The Board of Directors
Fred Hutchinson Cancer Center:

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited Fred Hutchinson Cancer center's (Fred Hutch's) compliance with the types of compliance requirements identified as subject to audit in the *OMB Compliance Supplement* that could have a direct and material effect on each of Fred Hutch's major federal programs for the year ended June 30, 2023. Fred Hutch's major federal programs are identified in the summary of auditors' results section of the accompanying schedule of findings and questioned costs.

In our opinion, Fred Hutch complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2023.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditors' Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of Fred Hutch and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of Fred Hutch's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to Fred Hutch's federal programs.

Auditors' Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on Fred Hutch's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute



assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about Fred Hutch's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding Fred Hutch's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of Fred Hutch's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of Fred Hutch's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Report on Internal Control Over Compliance

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditors' Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.



The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

We have audited the consolidated financial statements of Fred Hutch as of and for the year ended June 30, 2023, and have issued our report thereon dated October 13, 2023, which contained an unmodified opinion on those consolidated financial statements. Our audit was performed for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by the Uniform Guidance and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with GAAS. In our opinion, the schedule of expenditures of federal awards is fairly stated in all material respects in relation to the consolidated financial statements as a whole.

KPMG LLP

Seattle, Washington
October 13, 2023

FRED HUTCHINSON CANCER CENTER

Schedule of Expenditures of Federal Awards

Year ended June 30, 2023

Federal ALN or Grant	Federal grant/Pass-through grantor/program title	Passed-through to subrecipients	Expenditures
DIRECT RESEARCH AND DEVELOPMENT AWARDS:			
DEPARTMENT OF HEALTH AND HUMAN SERVICES / NATIONAL INSTITUTES OF HEALTH:			
10.310	NATIONAL INSTITUTE OF FOOD AND AGRICULTURE	\$ 124,126	536,046
12.420	DEPARTMENT OF DEFENSE - USA MEDICAL	532,318	8,267,475
12.431	DEPARTMENT OF DEFENSE - ARMY COMMAND	—	542,401
12.U01	DEPARTMENT OF DEFENSE - USA MEDICAL	—	(55,433)
47.074	NATIONAL SCIENCE FOUNDATION	—	604,195
64.U01	PALO ALTO VETERANS INST FOR RESEARCH	—	6,941
64.U02	US DEPARTMENT OF VETERANS AFFAIRS	—	30,380
64.U03	VA PUGET SOUND HEALTH CARE SYSTEM	—	10,055
64.U04	VA PUGET SOUND HEALTH CARE SYSTEM	—	12,805
93.103	U.S. FOOD AND DRUG ADMINISTRATION	328,049	649,570
93.113	NATL INST OF ENVIRONMENTAL HEALTH SCI	—	556,077
93.121	NATL INST OF DENTAL CRANIO RESEARCH	307,732	1,009,245
93.172	NATL HUMAN GENOME RESEARCH INSTITUTE	—	725,167
93.173	NATL INST ON DEAFNESS AND COMM DISORDER	40,919	1,151,873
93.242	NATL INST OF MENTAL HEALTH	139,292	459,280
93.279	NATIONAL INSTITUTE ON DRUG ABUSE	32,457	1,517,940
93.310	NATIONAL CANCER INSTITUTE	—	745,810
93.310	NATL CTR FOR ADVANCING TRANSLATIONAL SCI	—	4,157
93.351	OFFICE OF THE DIRECTOR, NIH	—	1,582,189
93.353	NATIONAL CANCER INSTITUTE	1,152,096	6,143,980
93.361	NATIONAL INSTITUTE OF NURSING RESEARCH	40,454	187,948
93.393	NATIONAL CANCER INSTITUTE	4,315,236	19,000,793
93.394	NATIONAL CANCER INSTITUTE	1,766,100	10,294,177
93.395	NATIONAL CANCER INSTITUTE	7,904,653	30,049,447
93.396	NATIONAL CANCER INSTITUTE	555,000	9,930,590
93.396	NATL INSTITUTE ON AGING	289,287	522,634
93.397	NATIONAL CANCER INSTITUTE	3,966,479	18,340,355
93.398	NATIONAL CANCER INSTITUTE	41,413	2,332,121
93.399	NATIONAL CANCER INSTITUTE	635,966	2,384,793
93.837	NATL HEART, LUNG AND BLOOD INSTITUTE	2,879,147	5,427,616
93.838	NATL HEART, LUNG AND BLOOD INSTITUTE	1,284,457	2,736,354
93.839	NATL HEART, LUNG AND BLOOD INSTITUTE	1,850,321	7,013,599
93.839	NATL INST OF DIAB AND DIGST AND KDNY DSE	—	(8,592)
93.846	NATL INST OF ARTH AND MUSC SKIN AND DSE	138,560	1,167,377
93.847	NATL INST OF DIAB AND DIGST AND KDNY DSE	177,807	4,979,063
93.853	NATL INST OF NEURO DISORDERS AND STROKE	407,650	2,897,114
93.855	NATL INST OF ALLERGY AND INFECTIOUS DSE	83,077,688	239,300,691
93.859	NATL INST OF GENERAL MEDICAL SCIENCES	100,187	12,094,733
93.865	NATL INST OF CHILD HEALTH & HUMAN DEV	1,212,335	1,984,287
93.866	NATL INSTITUTE ON AGING	6,510	3,563
93.879	NATIONAL LIBRARY OF MEDICINE	7,571	65,394
93.989	FOGARTY INTERNATIONAL CENTER	—	377,480
93.U01	CENTERS FOR DISEASE CONTROL AND PRV	118,114	291,470
93.U02	CENTERS FOR DISEASE CONTROL AND PRV	—	138,614
93.U03	NATIONAL CANCER INSTITUTE	—	7,018,599
93.U04	NATIONAL CANCER INSTITUTE	—	7,999
93.U05	NATIONAL CANCER INSTITUTE	178,980	4,575,371
93.U06	NATL HEART, LUNG AND BLOOD INSTITUTE	1,842,321	11,734,492
93.U07	NATL HEART, LUNG AND BLOOD INSTITUTE	—	67,100
93.U08	NATL HEART, LUNG AND BLOOD INSTITUTE	52,936	52,936
93.U09	NATL INST OF ALLERGY AND INFECTIOUS DSE	356,708	655,412
93.U36	NATL INST OF ALLERGY AND INFECTIOUS DSE	—	(26,486)
	Grant total - Direct Research and Development Funds	\$ 115,862,869	420,097,197
10	NATIONAL INSTITUTE OF FOOD AND AGRICULTURE	\$ 124,126	536,046
12	DEPARTMENT OF DEFENSE	532,318	8,754,443
47	NATIONAL SCIENCE FOUNDATION	—	604,195
64	US DEPARTMENT OF VETERANS AFFAIRS	—	60,181
93	DEPARTMENT OF HEALTH AND HUMAN SERVICES / NATIONAL INSTITUTES OF HEALTH	115,206,425	410,142,332
		\$ 115,862,869	420,097,197

FRED HUTCHINSON CANCER CENTER
Schedule of Expenditures of Federal Awards
Year ended June 30, 2023

Federal ALN or Grant	Pass-through Funds – Department of Health and Human Services and Other Federal Agencies	Passed-through entity or award identifying number	Passed-through to subrecipients	Expenditures
93.837	ALBERT EINSTEIN COLLEGE OF MEDICINE: CARDIOMETABOLIC OUTCOMES IN MULTI-ETHNIC PHYSICAL ACTIVITY AND SEDENTARY BEHAVIOR STUDY (COMPASS)	31159A	\$ —	122,319
93.U10	HISPANIC COMMUNITY HEALTH STUDY – STUDY OF LATINOS RESEARCH SUPPLEMENTS TO PROMOTE DIVERSITY IN HEALTH RELATED RESEARCH	312305	—	37,759
93.172	ALTIUS INSTITUTE FOR BIOMEDICAL SCIENCE: ENCODE MAPPING CENTER - A COMPREHENSIVE CATALOG OF DNASE I HYPERSENSITIVE SITES	PF8996	—	2,949
93.393	ARIZONA STATE UNIVERSITY: COUPLE COMMUNICATION IN CANCER: A MULTI-METHOD EXAMINATION	17-132	—	(461)
93.393	MODELING NEOPLASTIC PROGRESSION IN BARRETT'S ESOPHAGUS	ASUB00001309	—	6,439
12.420	BAYLOR COLLEGE OF MEDICINE: IDENTIFYING NOVEL CANCER PREDISPOSITION SYNDROME: AN INTEGRATIVE EPIDEMIOLOGIC AND GENOMIC APPROACH	7000001301	—	47,406
93.859	BECKMAN RESEARCH INSTITUTE - CITY OF HOPE: CYCLOPHOSPHAMIDE PHARMACOKINETICS AND PHARMACOMETABOLOMICS	60584.2005439.669302	—	(229)
93.396	PD-L1 INTERACTS WITH CD80 AND PD-1 TO REGULATE GVHD AND GVL ACTIVITY	60374.2004933.669301	—	(150)
93.855	BENAROYA RESEARCH INSTITUTE: IMMUNE TOLERANCE NETWORK	FY22ITN235	—	242,985
93.855	IMMUNE TOLERANCE NETWORK	FY23ITN235	—	89,088
93.855	IMMUNE TOLERANCE NETWORK	ITN235	—	(11,385)
93.396	BETH ISRAEL DEACONESS MEDICAL CENTER: PROJECT 1: DETERMINING AND EXPLOITING MECHANISMS OF AR-MEDIATED SUPPRESSION OF CELL PROLIFERATION AND SURVIVAL	01063975	—	115,899
93.396	PROJECT 1: DETERMINING AND EXPLOITING MECHANISMS OF AR-MEDIATED SUPPRESSION OF CELL PROLIFERATION AND SURVIVAL	GRT65241	—	124,802
93.393	BOSTON CHILDREN'S HOSPITAL: CAN RISK-REDUCING MEDICATIONS IMPROVE BREAST CANCER PREVENTION IN CHILDHOOD AND ADOLESCENT CANCER SURVIVORS? COMPARATIVE			
93.395	MODELING TO INFORM CARE	GENFD0002243198	—	34,388
93.395	GENETIC TESTING TO GUIDE PEDIATRIC CANCER CARE AND FOLLOW UP: USING ANTHRACYCLINE-ASSOCIATED CARDIAC TOXICITY AS A MODEL FOR THE FUTURE	GENFD0002243091	—	104,942
93.837	BOSTON UNIVERSITY: MITOCHONDRIAL DNA, NUCLEAR DNA METHYLATION, AND CARDIOMETABOLIC DISEASE TRAITS	4500004053	—	65,937
93.393	BRIGHAM & WOMEN'S HOSPITAL: HELICOBACTER INFECTION AND LIVER CANCER RISK AMONG AFRICAN AMERICANS AND WHITES IN THE UNITED STATES	125785	—	40,887
93.121	LONG TERM ORAL HEALTH OUTCOMES IN THE CHRONIC GVHD CONSORTIUM	121660	—	318,526
93.393	PERFLUOROALKYL SUBSTANCES (PFAS) AND LIVER CANCER RISK IN THE UNITED STATES	127445	—	26,910
93.394	BROAD INSTITUTE: ASSAY VALIDATION OF CELL-FREE DNA SHALLOW WHOLE GENOME SEQUENCING TO DETERMINE TUMOR FRACTION IN ADVANCED CANCERS	5000517-5500001458	—	(49)
93.394	ASSAY VALIDATION OF CELL-FREE DNA SHALLOW WHOLE GENOME SEQUENCING TO DETERMINE TUMOR FRACTION IN ADVANCED CANCERS	5001511-5500001817	—	6,025
93.847	BROWN UNIVERSITY: ASPROSIN, BODY WEIGHT, AND RISK OF TYPE 2 DIABETES IN U.S. MEN AND WOMEN	00001626	—	(6,172)
93.847	ASPROSIN, BODY WEIGHT, AND RISK OF TYPE 2 DIABETES IN U.S. MEN AND WOMEN	00002122	—	46,080
93.397	CASE WESTERN RESERVE UNIVERSITY: GENETIC DETERMINANTS OF BARRETT'S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA	RESS16224	—	(349)
93.397	GENETIC DETERMINANTS OF BARRETT'S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA	RESS16235	—	6,602
93.394	CEDARS-SINAI MEDICAL CENTER: MULTIPLEXED PROTEIN BIOMARKER-BASED ASSAY FOR THE DETECTION OF BLADDER CANCER	1932125	—	106,243
12.U02	CHIMEROCTE, INC.: IODIDE FOR THE TREATMENT OF INFLUENZA AND OTHER STRESSES	FH0003	—	116,348
93.838	CINCINNATI CHILDRENS HOSPITAL MEDICAL CR: TRANSPIRE: A PROSPECTIVE COHORT STUDY OF LUNG INJURY AFTER HEMATOPOIETIC STEM CELL TRANSPLANT IN CHILDREN	315648	—	15,104
93.393	COLUMBIA UNIVERSITY MEDICAL CENTER: COMPARATIVE MODELING FOR THE PREVENTION AND CONTROL OF UTERINE CANCER	2(GG017711-01)	—	4,285
93.393	COMPARATIVE MODELING FOR THE PREVENTION AND CONTROL OF UTERINE CANCER	2(GG017711-02)	—	12,576
93.393	IMPACT OF ALLOSTATIC LOAD AND NEIGHBORHOOD CONTEXTUAL FACTORS ON BREAST CANCER IN THE WOMEN'S HEALTH INITIATIVE	4(GG017291-01)	—	31,298
93.393	MULTICENTER TRIAL OF DECISION SUPPORT FOR BREAST CANCER CHEMOPREVENTION	2(GG015020-01)	—	64,277
93.866	CORNELL UNIVERSITY: A COMMUNICATION-BASED INTERVENTION FOR EARLY STAGE DEMENTIA PATIENT-CAREGIVER DYADS TO INCREASE ENGAGEMENT IN ADVANCE			
93.866	CARE PLANNING AND REDUCE CAREGIVER BURDEN	222487-02	—	38,299
93.866	A COMMUNICATION-BASED INTERVENTION FOR EARLY STAGE DEMENTIA PATIENT-CAREGIVER DYADS TO INCREASE ENGAGEMENT IN ADVANCE CARE			
93.866	PLANNING AND REDUCE CAREGIVER BURDEN	211724-1	—	(6,258)
93.837	ADAPTABLE TISSUE-SPECIFIC ENDOTHELIAL CELLS FOR ORGAN REGENERATION	221978	—	13,408
93.837	ADAPTABLE TISSUE-SPECIFIC ENDOTHELIAL CELLS FOR ORGAN REGENERATION	227884	—	1,812
93.855	EARLY LIFE B CELL RESPONSES AND INFLAMMATION FOLLOWING SARS-COV-2 INFECTION - COVID-19	224275-2	—	29,222
93.855	ENDOTHELIAL CELL TRANSPLANTATION FOR MULTI-ORGAN REPAIR TO COUNTER RADIATION INJURY	221979-1	—	307,184
93.855	ESCAPE OF MATERNAL PLASMA BROADLY NEUTRALIZING ANTIBODY AS A MECHANISM OF MOTHER TO CHILD HIV TRANSMISSION	224425-2	—	141,621
93.855	NEUTRALIZING AND NON-NEUTRALIZING ANTIBODY EFFECTOR FUNCTIONS IN HIV INFECTED CHILDREN	224320-1	—	89,780
93.855	NEUTRALIZING AND NON-NEUTRALIZING ANTIBODY EFFECTOR FUNCTIONS IN HIV INFECTED CHILDREN	224320-2	—	14,854
93.855	REACH: RESEARCH ENTERPRISE TO ADVANCE A CURE FOR HIV	222658	—	182,009
93.855	SCREENING FOR RESISTANT BACTERIA TO PERSONALIZE INFECTION PREVENTION STRATEGIES IN NEUTROPENIC PATIENTS	223319	—	134,430
93.855	SCREENING FOR RESISTANT ENTERIC BACTERIA TO PERSONALIZE INFECTION PREVENTION STRATEGIES IN NEUTROPENIC PATIENTS	213450	—	3,168

FRED HUTCHINSON CANCER CENTER
Schedule of Expenditures of Federal Awards
Year ended June 30, 2023

Federal ALN or Grant	Pass-through Funds – Department of Health and Human Services and Other Federal Agencies	Passed-through entity or award identifying number	Passed-through to subrecipients	Expenditures
93.421	COUNCIL STATE TERRITORIAL EPIDEMIOLOGIST: MATEHEMATICAL MODELING OF THE IMPACT OF INTEGRATED PREVENTION STRATEGIES AGAINST COVID-19 IN WASHINGTON AND OREGON	7719	\$ —	281,225
	DANA-FARBER CANCER INSTITUTE:			
93.172	BIOCONDUCTOR: AN OPEN-SOURCE, OPEN-DEVELOPMENT COMPUTING RESOURCE FOR GENOMICS	1318218	—	226,460
93.172	BIOCONDUCTOR: AN OPEN-SOURCE, OPEN-DEVELOPMENT COMPUTING RESOURCE FOR GENOMICS	1318219	—	120,180
93.394	BIOMARKER SCREENING ALGORITHMS FOR THE IMPROVED EARLY DETECTION OF HEPATOCELLULAR CARCINOMA	1308604	—	13,941
93.394	BIOMARKER SCREENING ALGORITHMS FOR THE IMPROVED EARLY DETECTION OF HEPATOCELLULAR CARCINOMA	AWOA	—	4,666
93.395	THE PROMOTING RESILIENCE IN STRESS MANAGEMENT (PRISM) INTERVENTION: A MULTI-SITE RANDOMIZED CONTROLLED TRIAL FOR ADOLESCENTS AND YOUNG ADULTS WITH ADVANCED CANCER	AWOA	—	2,988
	DUKE UNIVERSITY:			
93.393	DELINEATING THE UNDERLYING REASONS FOR THE RACIAL DISPARITY IN GASTRIC CANCER INCIDENCE IN THE UNITED STATES	303001283	—	46,311
93.397	DUKE CANCER HEALTH DISPARITIES P20 SPORE	303000938	—	48,072
93.397	DUKE CANCER HEALTH DISPARITIES P20 SPORE	303000957	—	46,875
93.397	DUKE CANCER HEALTH DISPARITIES P20 SPORE	A033900	—	(50,543)
93.855	NEONATAL IMMUNITY TO NOVEL TF SHIVS	303001951	—	15,142
93.855	NEUTRALIZING AND NON-NEUTRALIZING ANTIBODY EFFECTOR FUNCTIONS IN HIV INFECTED CHILDREN	A031494	—	2,103
	ECOG-ACRIN CANCER RESEARCH GROUP:			
93.395	PURCHASE SERVICE AGREEMENT BETWEEN ECOG-ACRIN AND FRED HUTCHINSON EMORY UNIVERSITY:	ECOG-ACRIN MASTER PS	—	8,775
93.855	COVID 19 - LEADERSHIP GROUP FOR THE INFECTIOUS DISEASES CLINICAL RESEARCH CONSORTIUM (IDCRCLG) - MODERNA BOOST SUB-STUDY ASSAY 20-0003	A535101	—	73,510
93.855	COVID 19 - LEADERSHIP GROUP FOR THE INFECTIOUS DISEASES CLINICAL RESEARCH CONSORTIUM (IDCRCLG) - MODERNA VARIANT OVERSIGHT	A557682	—	(60,009)
93.855	COVID-19 - LEADERSHIP GROUP FOR THE INFECTIOUS DISEASES CLINICAL RESEARCH CONSORTIUM (IDCRCLG)	A650499	—	171,947
93.855	COVID-19 - LEADERSHIP GROUP FOR THE INFECTIOUS DISEASES CLINICAL RESEARCH CONSORTIUM (IDCRCLG) - MIX & MATCH ASSAYS	A614153	—	976,168
93.855	COVID-19 - LEADERSHIP GROUP FOR THE INFECTIOUS DISEASES CLINICAL RESEARCH CONSORTIUM (IDCRCLG) - MOMI-VAX STUDY	A611924	—	202,075
93.855	COVID-19 - LEADERSHIP GROUP FOR THE INFECTIOUS DISEASES CLINICAL RESEARCH CONSORTIUM (IDCRCLG) COVAIL	A613388	—	22,232
93.855	COVID-19 - LEADERSHIP GROUP FOR THE INFECTIOUS DISEASES CLINICAL RESEARCH CONSORTIUM (IDCRCLG) S3 GRITSTONE, VARIANT AND PEDIATRIC VACCINE TRIALS DMID PROTOCOL #21-0002-LOURIC VACCINE TRIALS	A639553	—	245,396
93.855	COVID-19 - LEADERSHIP GROUP FOR THE INFECTIOUS DISEASES CLINICAL RESEARCH CONSORTIUM (IDCRCLG) S3 GRITSTONE, VARIANT AND PEDIATRIC VACCINE TRIALS DMID PROTOCOL #20-0034 OVERSIGHT	A662504	—	122,864
93.855	COVID-19- IMMUNOLOGICAL MEMORY TO COVID-19	A514517	—	144,562
93.855	COVID-19- LEADERSHIP GROUP FOR THE INFECTIOUS DISEASES CLINICAL RESEARCH CONSORTIUM (IDCRCLG) - MIX AND MATCH OVERSIGHT	A614770	—	121,786
93.855	COVID-19-LEADERSHIP GROUP FOR THE INFECTIOUS DISEASES CLINICAL RESEARCH CONSORTIUM (IDCRCLG) S3 GRITSTONE, VARIANT & PEDIATRIC VACCINE TRIALS DMID PROTOCOL #21-0002 OVERSIGHT	A659486	—	147,543
93.855	DESIGN AND ANALYSIS OF VACCINE TRIALS FOR EMERGING INFECTIOUS DISEASE THREATS	A538222	—	123,631
93.855	DYNAMICS AND EVOLUTION OF IMMUNE RESPONSES TO INFLUENZA VIRUSES	A653114	—	114,964
93.855	IDCRC COVID PROTOCOLS - CYANVAC DEV. OVERSIGHT - LEDERSHIP GROUP FOR THE INFECTIOUS DISEASES CLINICAL RESEARCH CONSORTIUM (IDCRCLG)	A803507	—	21,428
93.855	IDCRC NON-COVID PROTOCOLS	A639490	—	139,825
93.855	IDCRC NON-COVID PROTOCOLS	A758236	—	202,350
93.855	INFECTIOUS DISEASES CLINICAL RESEARCH CONSORTIUM LEADERSHIP GROUP: MIX AND MATCH - COVID-19	A660158	—	2,257,789
93.855	LEADERSHIP GROUP FOR AN INFECTIOUS DISEASES CLINICAL RESEARCH CONSORTIUM (IDCRCLG) - CORE	A605961	—	116,775
93.855	LEADERSHIP GROUP FOR THE INFECTIOUS DISEASES CLINICAL RESEARCH CONSORTIUM (IDCRCLG)	A603407	—	130,413
93.855	LEADERSHIP GROUP FOR THE INFECTIOUS DISEASES CLINICAL RESEARCH CONSORTIUM (IDCRCLG)	A639509	—	431,179
93.855	LEADERSHIP GROUP FOR THE INFECTIOUS DISEASES CLINICAL RESEARCH CONSORTIUM (IDCRCLG) - COVID-19	A756806	—	696,266
93.855	LEADERSHIP GROUP FOR THE INFECTIOUS DISEASES CLINICAL RESEARCH CONSORTIUM (IDCRCLG) - GRITSTONE OVERSIGHT	A549810	—	(48,986)
93.855	LEADERSHIP GROUP FOR THE INFECTIOUS DISEASES CLINICAL RESEARCH CONSORTIUM (IDCRCLG) COVID 19 SUPPLEMENT	A390444	—	9,817
93.855	LEADERSHIP GROUP FOR THE INFECTIOUS DISEASES CLINICAL RESEARCH CONSORTIUM (IDCRCLG) MOMI-VAX	A611876	—	914,089
93.855	LEADERSHIP GROUP FOR THE INFECTIOUS DISEASES CLINICAL RESEARCH CONSORTIUM (IDCRCLG) RESTRICTED SUPPLEMENT	A660510	—	(9,817)
93.855	LEADERSHIP GROUP FOR THE INFECTIOUS DISEASES CLINICAL RESEARCH CONSORTIUM (IDCRCLG) S3 GRITSTONE, VARIANT AND PEDIATRIC VACCINE TRIALS - COVID-19	A639529	—	268,334
93.855	LEADERSHIP GROUP FOR THE INFECTIOUS DISEASES CLINICAL RESEARCH CONSORTIUM (IDCRCLG) S3 GRITSTONE, VARIANT AND PEDIATRIC VACCINE TRIALS DMID PROTOCOL #20-0034	A621244	—	8,893
93.855	LEADERSHIP GROUP FOR THE INFECTIOUS DISEASES CLINICAL RESEARCH CONSORTIUM (IDCRCLG) SDSU	A754612	—	135,707
93.855	LEADERSHIP GROUP FOR THE INFECTIOUS DISEASES CLINICAL RESEARCH CONSORTIUM (IDCRCLG) 2022-0013, COVID INTRANASAL	A803579	—	5,055
93.855	LEADERSHIP GROUP FOR THE INFECTIOUS DISEASES CLINICAL RESEARCH CONSORTIUM (IDCRCLG)-LOU YEAR 4	A756975	—	176,453
93.855	QUANTIFYING THE EPIDEMIOLOGICAL IMPACT OF TARGETED INDOOR RESIDUAL SPRAYING ON AEDES-BORNE DISEASES	A661118	—	38,472
93.855	QUANTIFYING THE EPIDEMIOLOGICAL IMPACT OF TARGETED INDOOR RESIDUAL SPRAYING ON AEDES-BORNE DISEASES	A801409	—	10,499
93.855	STATISTICAL METHODS FOR EVALUATING VACCINE EFFICACY AGAINST ASYMPTOMATIC AND SYMPTOMATIC INFECTIONS USING INFREQUENT DIAGNOSTIC TESTING DATA	A780849	—	63,352
93.855	VACCINE INDUCED IMMUNITY IN THE YOUNG AND AGED	A712193	—	691,361
	EPICYPHER:			
93.172	DEVELOPMENT OF EFFICIENT QUANTITATIVE CHROMATIN PROFILING IN KIT AND HIGH-THROUGHPUT FORMATS	R44HG010640-FHCRC	—	225,980
93.121	DEVELOPMENT OF NOVEL SPIKE-IN CONTROLS FOR QUANTITATIVE CHROMATIN ASSOCIATED PROTEIN PROFILING	NA	—	72,186
93.855	DEVELOPMENT OF ULTRA-EFFICIENT ANTIBODIES FOR SINGLE CELL MAPPING APPLICATIONS	A1174357-FHCRC	—	28,216
93.855	DEVELOPMENT OF ULTRA-EFFICIENT ANTIBODIES FOR SINGLE CELL MAPPING APPLICATIONS	NA	—	(123)
93.859	SINGLE-CELL CHROMATIN MAPPING ASSAYS	GM140536-FHCC	—	284,964

FRED HUTCHINSON CANCER CENTER
Schedule of Expenditures of Federal Awards
Year ended June 30, 2023

Federal ALN or Grant	Pass-through Funds – Department of Health and Human Services and Other Federal Agencies	Passed-through entity or award identifying number	Passed-through to subrecipients	Expenditures
93.855	FAMILY HEALTH INTERNATIONAL (FH360):			
	HPTN 083 SUPPLEMENT	PO22002959	\$ —	1,516,128
93.855	HPTN 084	PO22002960	—	1,351,639
93.855	HPTN 084 PREGNANCY SUPPLEMENT	PO22003564	—	922,598
93.855	HPTN 096 SUPPLEMENT	PO22002961	—	421,249
	GEORGETOWN UNIVERSITY:			
93.353	A RANDOMIZED TRIAL OF A MOBILE HEALTH AND SOCIAL MEDIA PHYSICAL ACTIVITY INTERVENTION AMONG ADOLESCENT AND YOUNG ADULT CHILDHOOD CANCER SURVIVORS	424984_GR424785-FHCRC	—	10,555
93.353	A RANDOMIZED TRIAL OF A MOBILE HEALTH AND SOCIAL MEDIA PHYSICAL ACTIVITY INTERVENTION AMONG ADOLESCENT AND YOUNG ADULT CHILDHOOD CANCER SURVIVORS	425375_GR424785-FHCRC	—	74,748
	HEALTH RESEARCH, INC. ROSWELL PARK DIVIS:			
93.213	FLAXSEED EFFECTS ON GUT MICROBIAL METABOLISM AND CIRCULATING INFLAMMATION-RELATED METABOLIC PROFILES IN AFRICAN AMERICAN AND NON-HISPANIC WHITE WOMEN	315-01	—	53,101
	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI:			
93.394	PROTEOGENOMIC TRANSLATOR FOR CANCER BIOMARKER DISCOVERY TOWARDS PRECISION MEDICINE	0255-G561-4609	—	19,697
93.394	PROTEOGENOMIC TRANSLATOR FOR CANCER BIOMARKER DISCOVERY TOWARDS PRECISION MEDICINE	0255-G562-4609	—	1,944
	ICF ESAC, LLC:			
93.U11	ESAC DATA COORDINATING CENTER FOR CLINICAL PROTEOMIC TECHNOLOGIES FOR CANCER PROGRAM	55926	—	13,768
93.U12	ESAC DATA COORDINATING CENTER FOR CLINICAL PROTEOMIC TECHNOLOGIES FOR CANCER PROGRAM	LBR-PDC2-05	—	4,160
	INSTITUTE FOR SYSTEMS BIOLOGY:			
93.847	CYBERGLUT: TOWARDS PERSONALIZED HUMAN-MICROBIOME METABOLIC MODELING FOR PRECISION HEALTH AND NUTRITION	2022-0004	—	114,874
93.394	LIQUID BIOPSY-BASED TOOLKITS FOR NEOANTIGEN AND COGNATE TCR DISCOVERY FOR CANCER IMMUNOTHERAPY	2021.0015	—	8,361
93.394	NANO AND BIOMOLECULAR ENGINEERED TECHNOLOGIES FOR NEOANTIGEN-SPECIFIC T CELL CAPTURE AND CHARACTERIZATION	2021.0007	—	246,083
	INTERNATIONAL AGENCY FOR RESEARCH ON CAN:			
93.393	INTEGRATIVE ANALYSIS OF LUNG CANCER ETIOLOGY AND RISK - BIOMARKERS OF LUNG CANCER RISK (LC3-II)	CRA/GEP/2020/1	—	16,581
93.394	THE LUNG EARLY PROTEINS PROJECT: A LEAP TOWARDS IMPLEMENTING BIOMARKERS IN LUNG CANCER SCREENING	CRA-GEM-2022-16	—	25,944
	JOHNS HOPKINS UNIVERSITY:			
93.172	IMPLEMENTING THE GENOMIC DATA SCIENCE ANALYSIS, VISUALIZATION, AND INFORMATICS LAB-SPACE (ANVIL)	2005537847	—	6,542
93.172	IMPLEMENTING THE GENOMIC DATA SCIENCE ANALYSIS, VIZUALIZATION, AND INFORMATICS LAB-SPACE (ANVIL)	2005537847	—	440,015
	KAISER FOUNDATION RESEARCH INSTITUTE:			
93.393	AN ELECTRONIC HEALTH RECORD-BASED TOOL TO IDENTIFY NEWLY DIAGNOSED BREAST CANCER PATIENTS AT RISK OF LOW SOCIAL SUPPORT	210853-FHCRC-03	—	46,742
93.393	ASSESSING THE LONG-TERM IMPACTS OF THE COVID-19 PANDEMIC ON DISPARITIES IN CANCER SCREENING AND FOLLOWUP (RESTORE)	OOS030571-FHCC-01	—	87,979
93.393	BREAST WHITE ADIPOSE TISSUE INFLAMMATION AND BREAST CANCER OUTCOMES	RNG210667-FHCRC	—	107,415
93.393	CLINICAL CARE GAPS AND UNMET NEEDS IN ADOLESCENT AND YOUNG ADULT (AYA) CANCERS	RNG211062-FHCRC-01	—	16,636
93.855	KAISER WASHINGTON VACCINE AND TREATMENT EVALUATION UNIT	RNG210453-FH	—	23,912
93.393	MULTILEVEL INTERVENTIONS TO INCREASE ADHERENCE TO LUNG CANCER SCREENING	RNG211471-FHCC	—	22,792
93.393	PREDICTORS OF CVD AMONG BREAST CANCER SURVIVORS IN AN INTEGRATED HEALTH SYSTEM	RNG209338-FHCRC-01	—	33,538
	LA JOLLA INSTITUTE FOR IMMUNOLOGY:			
93.855	FUNCTIONAL AND DYSFUNCTIONAL HUMAN CD4 T CELL AND B CELL RESPONSES TO BACTERIA AND VIRUSES	27440-03-107-382	—	1,268,934
	LEIDOS BIOMEDICAL RESEARCH, INC:			
93.U13	CENTRALIZED DIAGNOSTIC AND MONITORING TESTING FOR ACUTE MYELOID LEUKEMIA	20X088F, TASK ORDER F1	—	150,726
93.U14	GENEXUS ASSAY DEVELOPMENT FOR MDNET MYELOMATCH PRECISION MEDICINE INITIATIVE	20X088F, TASK ORDER F2	—	510,828
93.U15	IMPLEMENT, OPERATIONALIZE, AND MAINTAIN INFRASTRUCTURE TO SUPPORT MDNET MYELOMATCH ASSAYS AND ANALYSES; CYTOGENETIC ANALYSIS OF MDNET MYELOMATCH SPECIMENS; AND NCI MYELOID ASSAY (GENEXUS MYELOID NGS) ANALYSIS OF MDNET MYELOMATCH SPECIMENS	20X088F, TASK ORDER F3	—	229,679
93.U16	MECHANISTIC STUDIES OF RCAS/TV-A DRIVEN BRAIN TUMORS	21X162-Q2	—	361,313
93.U17	MECHANISTIC STUDIES OF RCAS/TV-A DRIVEN BRAIN TUMORS	21X162-Q3	—	437,439
93.U18	MECHANISTIC STUDIES OF RCAS/TV-A DRIVEN BRAIN TUMORS - TASK ORDER Q4	21X162-Q4	—	70,142
93.U19	MOUSE BRAIN CANCER MODELS FROM MOLECULAR ENGINEERING TO SUPPORT THE DIVISION OF CANCER TREATMENT AND DIAGNOSIS - TASK ORDER 1	21X162_TO-Q1	—	87,991
	MAGEE-WOMEN'S RESEARCH INSTITUTE & FOUND:			
93.855	SDMC: MICROBICIDE TRIALS NETWORK MANAGEMENT AND SUPPORT (MTN)	9754	—	2,870,965
	MASSACHUSETTS GENERAL HOSPITAL:			
93.393	ASSESSING THE EFFECT OF VIRTUAL NAVIGATION INTERVENTIONS TO IMPROVE HEALTH INSURANCE LITERACY AND DECREASE FINANCIAL BURDEN: A CCSS RANDOMIZED TRIAL	241088	—	58,096
93.855	IMMUNE CORRELATES OF TUBERCULOSIS AND NON-TUBERCULOSIS INFECTIOUS MORBIDITY IN SOUTHERN AFRICAN HIV-EXPOSED, UNINFECTED INFANTS	234124	—	54,658
93.395	RANDOMIZED TRIAL INPATIENT PALLIATIVE CARE FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION	233094	—	188,272
93.394	TDNA IN UTERINE LAVAGE AND SERUM PROTEINS IN EARLY DETECTION OF OVARIAN CANCER	231339	—	31,945
93.837	TOPMED OMICS OF CARDIOVASCULAR DISEASE IN DIABETES	236957	—	26,591
93.847	TOPMED OMICS OF TYPE 2 DIABETES AND QUANTITATIVE TRAITS	238171	—	22,269
	MAYO CLINIC:			
93.393	RELATING MOLECULAR SUBGROUPS OF ENDOMETRIOSIS-ASSOCIATED OVARIAN CANCERS TO SURVIVAL AND RISK	FRE-277978-01	—	28,521
93.393	RELATING MOLECULAR SUBGROUPS OF ENDOMETRIOSIS-ASSOCIATED OVARIAN CANCERS TO SURVIVAL AND RISK	FRE-277978-03	—	22,086
	McGILL UNIVERSITY:			
93.855	QUANTIFYING THE BREADTH AND DURATION OF IMMUNITY INDUCED BY MENINGOCOCCAL B VACCINES	PT 86060	—	29,876
93.855	QUANTIFYING THE BREADTH AND DURATION OF IMMUNITY INDUCED BY MENINGOCOCCAL B VACCINES	PT86060	—	23,023
	MEDICAL UNIVERSITY OF SOUTH CAROLINA:			
93.395	TRANSLATING NOVEL DRUG-TARGETABLE BIOMARKERS TO TREAT GRAFT VERSUS HOST DISEASE	A21-0049-S002	—	37,312

FRED HUTCHINSON CANCER CENTER
Schedule of Expenditures of Federal Awards
Year ended June 30, 2023

Federal ALN or Grant	Pass-through Funds – Department of Health and Human Services and Other Federal Agencies	Passed-through entity or award identifying number	Passed-through to subrecipients	Expenditures
93.396	MISSION BIO: MEASURABLE RESIDUAL DISEASE TESTING FOR ACUTE MYELOID LEUKEMIA WITH SINGLE-CELL GENOTYPING	7135NIH PHASE 1	\$ —	37
93.855	MONTANA STATE UNIVERSITY: CYTOTOXIC IMMUNOCONJUGATES TO DEplete PERSISTENT HIV RESERVOIRS	G173-18-W7010	—	221,406
93.839	NATIONAL MARROW DONOR PROGRAM: CIBMTR STUDY NUMBER 17-SIBS: IDENTIFYING PREDICTORS OF POOR HEALTH-RELATED QUALITY-OF-LIFE AMONG PEDIATRIC HEMATOPOIETICS STEM CELL DONORS - FIXED PRICE	17-SIBS	—	16,505
12.300	MOLECULAR EVALUATION OF AML PATIENTS AFTER STEM CELL TRANSPLANT TO UNDERSTAND RELAPSE EVENTS (MEASURE)	NA	—	3,345
93.839	TRANSPLANT CENTER CLINICAL STUDY AGREEMENT	NA	—	176,265
93.395	NORTHWESTERN UNIVERSITY: A RETROSPECTIVE MONTE CARLO DOSIMETRY FOR LATE EFFECTS IN WILMS TUMOR PATIENTS	60047359 FHCRC	—	101,608
93.395	NRG ONCOLOGY: NRG ONCOLOGY FIXED PRICE SUBAWARD AGREEMENT	NA	—	13,925
93.855	OREGON HEALTH & SCIENCE UNIVERSITY: DEVELOPMENT OF AN MRNA-BASED THERAPEUTIC HIV/AIDS VACCINE	1016695_FHCRC	—	25,251
93.395	EFFECT OF IMMUNE-ENHANCING NUTRITION ON RADICAL CYSTECTOMY OUTCOMES	1010653_FHCC	—	8,967
93.855	IMMUNOLOGIC AND VIROLOGIC BASIS OF RHC/MV/SIV VACCINE-INDUCED REPLICATION ARREST EFFICACY	1022434_FHCC	—	42,342
93.855	INTEGRATING HUMAN AND NON-HUMAN PRIMATE DATA TO UNDERSTAND THE ACQUISITION OF PRE-ERYTHROCYTIC IMMUNITY IN THE FACE OF PREVIOUS MALARIA EXPOSURE	1020009_FHCRC	—	133,224
93.394	INTEGRATION INVESTIGATIONAL MIR371A-3P WITH CONVENTIONAL RADIOLOGY IMAGING FOR EARLIER AND MORE PRECISE DETECTION OF ACTIVE GERM CELL MALIGNANCY: A BCC/SWOG/S1823 SECONDARY USE OF DATA COLLABORATION	1019566_FHCC	—	2,192
93.394	INTEGRATION INVESTIGATIONAL MIR371A-3P WITH CONVENTIONAL RADIOLOGY IMAGING FOR EARLIER AND MORE PRECISE DETECTION OF ACTIVE GERM CELL MALIGNANCY: A BCC/SWOG/S1823 SECONDARY USE OF DATA COLLABORATION	1019566_FHCC	—	14,493
93.855	OPTIMIZING THE DEPLETION OF INNATE IMMUNE EFFECTOR CELLS IN NONHUMAN PRIMATES	1021803_FHCC	—	74,596
93.399	SWOG NCORP RESEARCH BASE	1014562_FHCRC LYMAN	—	1,407
93.399	SWOG NCORP RESEARCH BASE	1014562_FHCRC NEUHouser	—	36,358
93.399	SWOG NCORP RESEARCH BASE	1014562_SWOG_FREDHUTCH	—	27,151
93.399	SWOG NCORP RESEARCH BASE - EXECUTIVE COMMITTEE	1014562_FHCRC LYMAN	—	7,227
93.399	SWOG NCORP RESEARCH BASE (CCDR)	1014562_FHCRC UNGER	300,833	847,391
93.399	SWOG NCORP RESEARCH BASE (CTP)	1014562_FHCRC TANGEN	1,448,335	2,555,420
93.399	SWOG NCORP RESEARCH BASE- CCDR COMMITTEE	1014562_FHCRC RAMSEY	—	2,906
93.399	SWOG NCORP RESEARCH BASE- EXECUTIVE COMMITTEE	1014562_FHCRC RAMSEY	—	35,380
93.399	SWOG NCORP RESEARCH BASE: PROTOCOL DEVELOPMENT	1014562_FHCRC RAMSEY_A4	—	29,658
93.395	SWOG NETWORK GROUP OPERATIONS CENTER FOR THE NCTN	1013080_FHCRC	—	7,777
93.395	SWOG NETWORK GROUP OPERATIONS CENTER OF THE NCTN	1013080_FHCRC LYMAN	—	15,409
93.395	SWOG NETWORK GROUP OPERATIONS CENTER OF THE NCTN	1013080_SWOG_FREDHUTCH	—	22,500
93.395	SWOG NETWORK GROUP OPERATIONS CENTER OF THE NCTN: BIQSFP STUDY S1929	1013080-014_FHCRC	—	58,459
93.395	SWOG NETWORK GROUP OPERATIONS CENTER OF THE NCTN: S1612 - BIQSFP NON REAL-TIME INTEGRATED PROJECTS FOR SWOG NCTN GRANT YEAR 08	1013080-024_FHCRC	—	698,067
93.395	SWOG OHSU PURCHASE SERVICE AGREEMENT	SWOG MASTER PSA	—	4,001
93.393	PEACEFULLY, INC.: A COMPREHENSIVE WEB BASED PROGRAM TO HELP ADVANCED CANCER PATIENTS PLAN FOR END OF LIFE	NA	—	57,862
93.393	PENNSYLVANIA STATE UNIVERSITY: HPV ECHO: INCREASING THE ADOPTION OF EVIDENCE-BASED COMMUNICATION STRATEGIES FOR HPV VACCINATION IN RURAL PRIMARY CARE PRACTICES	FHCRC253279	—	26,048
93.395	PUBLIC HEALTH INSTITUTE: COG NCTN HM-ITSC INTEGRATED TRANSLATIONAL SCIENCE CENTER FOR HEMATOPOIETIC MALIGNANCIES IN CHILDREN	AR12173	—	48,032
93.395	COG NCTN NETWORK GROUP OPERATIONS CENTER COMMITTEE LEADERSHIP	AR10902	—	16,010
93.395	COG NCTN NETWORK GROUP OPERATIONS CENTER SCIENTIFIC COUNCIL	AR10395	—	16,010
93.395	COG NCTN YEAR 9 BIQSFP SUPPLEMENT AND PROGRESS REPORT	AR14105	—	70,287
93.395	COG NCTN NETWORK GROUP OPERATIONS CENTER	AR10904	—	30,005
93.395	COG NCTN NETWORK GROUP OPERATIONS CENTER	AR65375	—	12,436
93.395	COG SCIENTIFIC COUNCIL	AR64207	—	2,651
93.395	COG SCIENTIFIC COUNCIL Y7 PHI	AR10394	—	15,360
93.395	HEM-ITSC DATA ANALYSIS, VISUALIZATION AND TARGET DISCOVERY PLATFORM	AR64026	—	83,274
93.U20	Q2 SOLUTIONS: STAGE 2 CORRELATES ANALYSIS FOR COVID-19 TRIALS	NA	—	235,544
93.394	RESEARCH INST @ NATIONWIDE CHILDRENS HOS: SWOG BIOSPECIMEN BANK	700225-0323-00	—	80,521
93.394	SWOG BIOSPECIMEN BANK TO SUPPORT NCI NCTN	AWOA	—	14,389
93.172	RUTGERS, THE STATE UNIVERSITY: PAGE III: POPULATION ARCHITECTURE USING GENOMICS AND EPIDEMIOLOGY	1201_PO1277733	—	259,659
93.350	SEATTLE CHILDREN'S HOSPITAL: ACCELERATE CELLULAR IMMUNOTHERAPY DEVELOPMENT FOR TREATMENT OF LIFE-THREATENING CHILDHOOD DISORDERS	12666SUB	—	5,766
93.350	ACCELERATE CELLULAR IMMUNOTHERAPY DEVELOPMENT FOR TREATMENT OF LIFE-THREATENING CHILDHOOD DISORDERS	12882SUB	—	92,008
93.855	COLLECTIVE RESPONSES TO MALARIA VACCINATION	12982SUB	—	305,788
93.855	COVID-19 - IMMUNE RESPONSES TO MALARIA, HIV AND SARS-COV-2 INFECTION AND IMMUNIZATION	12959SUB	—	406,032
93.855	COVID-19 - IMMUNE RESPONSES TO MALARIA, HIV AND SARS-COV-2 INFECTION AND IMMUNIZATION	13126SUB	—	30,144
93.855	COVID-19 - IMMUNE RESPONSES TO MALARIA, HIV AND SARS-COV-2 INFECTION AND IMMUNIZATION - CLINICAL CORE	13125SUB	—	63,652

FRED HUTCHINSON CANCER CENTER
Schedule of Expenditures of Federal Awards
Year ended June 30, 2023

Federal ALN or Grant	Pass-through Funds – Department of Health and Human Services and Other Federal Agencies	Passed-through entity or award identifying number	Passed-through to subrecipients	Expenditures
93.855	COVID-19 IMMUNE RESPONSES TO MALARIA, HIV AND SARS-COV-2 INFECTION AND IMMUNIZATION - CLINICAL CORE	12960SUB	\$ —	243,524
93.855	DEVELOPMENT OF THE HIPC DATABASE AND RESEARCH PORTAL	12690SUB	—	9,450
93.855	EDUCATION OF THE FETAL IMMUNE SYSTEM BY INHERITED MATERNAL CELLS	12977SUB	—	20,510
93.395	ENGINEERING KNOTTED PEPTIDE THERAPEUTICS FOR PEDIATRIC BRAIN TUMOR PATIENTS	12795SUB	—	26,871
93.847	FIT 5 KIDS SCREEN TIME REDUCTION CURRICULUM FOR LATINO PRESCHOOLERS: A RCT	11792SUB	—	69,489
93.395	HIV INTEGRATION MODULATES IMMUNE REGULATION IN CANCER	11538SUB	—	15,491
93.U21	IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB)	12388SUB	—	11,240
93.U22	IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB)	12701SUB	—	98,258
93.U23	IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB)	12718SUB	—	114,115
93.U24	IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB)	12931SUB	—	153,315
93.855	IMMUNE RESPONSE TO MALARIA AND HIV INFECTION AND IMMUNIZATION - PROJECT 2 - YEAR 5	12687SUB	—	(6,120)
93.855	IMMUNE RESPONSES TO MALARIA AND HIV INFECTION AND IMMUNIZATION - CLINICAL CORE	12688SUB	—	(340)
93.855	IMMUNE RESPONSES TO MALARIA AND HIV INFECTION AND IMMUNIZATION: DATA MANAGEMENT AND ANALYSIS CORE	12689SUB	—	4,535
93.855	IMMUNE RESPONSES TO MALARIA, HIV AND SARS-COV-2 INFECTION AND IMMUNIZATION	AWOA	—	10,026
93.855	IMMUNE RESPONSES TO MALARIA, HIV AND SARS-COV-2 INFECTION AND IMMUNIZATION - SERVICE CORE - COVID-19	12975SUB	—	91,520
93.855	IMMUNE RESPONSES TO MALARIA, HIV AND SARS-COV-2 INFECTION AND IMMUNIZATION: DATA MANAGEMENT (DMAC) CORE	12961SUB	—	68,885
93.855	IMMUNE RESPONSES TO MALARIA, HIV AND SARS-COV-2 INFECTION AND IMMUNIZATION: DATA MANAGEMENT (DMAC) CORE	13130SUB	—	3,223
93.865	INFLUENCE OF HIV INFECTION ON VAGINAL VIROME AND RISK OF PRETERM BIRTH IN PREGNANT SOUTH AFRICAN WOMEN	12747SUB	—	16,994
93.847	INVESTIGATING MECHANISMS OF VACCINE RESPONSE DEFICIENCY IN CYSTIC FIBROSIS	12686SUB	—	(1,875)
93.855	MULTIPLEXED IMMUNO-SRM SCREENING FOR PRIMARY IMMUNODEFICIENCIES	11347SUB	—	(17,398)
93.395	TESTICULAR EFFECTS OF MODERN CHEMOTHERAPY REGIMENS IN OSTEOSARCOMA SURVIVORS	12815SUB	—	(152)
93.395	THE PROMOTING RESILIENCE IN STRESS MANAGEMENT (PRISM) INTERVENTION: A MULTI-SITE RANDOMIZED CONTROLLED TRIAL FOR ADOLESCENTS AND YOUNG ADULTS WITH ADVANCED CANCER	11991SUB	—	17,365
93.395	THE PROMOTING RESILIENCE IN STRESS MANAGEMENT (PRISM) INTERVENTION: A MULTI-SITE RANDOMIZED CONTROLLED TRIAL FOR ADOLESCENTS AND YOUNG ADULTS RECEIVING HEMATOPOIETIC CELL TRANSPLANTATION	11908SUB	—	22,715
93.847	TRANSLATIONAL RESEARCH CENTER TO EXPEDITE NOVEL THERAPIES IN CYSTIC FIBROSIS	12966SUB	—	16,526
93.847	TRANSLATIONAL RESEARCH CENTER TO EXPEDITE NOVEL THERAPIES IN CYSTIC FIBROSIS (P30)	12967SUB	—	58,257
93.839	ULTRASOUND-MEDIATED GENE DELIVERY TO ACHIEVE THERAPEUTIC CORRECTION OF HEMOPHILIA A	12266SUB	—	61,091
93.855	VIRAL AND IMMUNE KINETICS IN RHINOVIRUS INFECTION FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION	12504SUB	—	171,279
	SEATTLE INST FOR BIOMEDICAL & CLIN RES:			
93.393	IMPROVING THE REACH AND EFFECTIVENESS OF SMOKING CESSATION SERVICES TARGETED TO VETERANS LIVING WITH HIV	CK11-FHCRC-3	—	1,998
93.393	IMPROVING THE REACH AND EFFECTIVENESS OF SMOKING CESSATION SERVICES TARGETED TO VETERANS LIVING WITH HIV	CK11-FHCRC-4	—	10,610
	SLOAN-KETTERING INSTITUTE FOR CANCER RES:			
93.855	AI-DRIVEN STRUCTURALLY-ENABLED ANTIVIRAL PLATFORM (ASAP), PROJECT 1: ANTIVIRAL TARGETING TO SUPPRESS DRUG RESISTANCE	AWOA	—	3,666
93.393	COMPARATIVE MODELING OF EFFECTIVE POLICIES FOR COLORECTAL CANCER CONTROL	MSKSUB00000159	—	164,395
93.393	COMPARATIVE MODELING OF EFFECTIVE POLICIES FOR COLORECTAL CANCER CONTROL - CISNET RAPID RESPONSE: AGA ANALYSIS - REVISION-2	REQ-1984354	—	6,767
93.393	COMPARATIVE MODELING OF EFFECTIVE POLICIES FOR COLORECTAL CANCER CONTROL - RAPID RESPONSE - REVISION-1	C22302855	—	17,774
93.396	INTERROGATING THE MINOR SPLICEOSOME TO UNDERSTAND AND TREAT LEUKEMIA	BD527367A	—	381
93.396	INTERROGATING THE MINOR SPLICEOSOME TO UNDERSTAND AND TREAT LEUKEMIA	SUB00000383AM4-REV	—	384,688
93.839	MACHINE LEARNING WITH IMMUNOGENETICS FOR THE PREDICTION OF HEMATOPOIETIC CELL TRANSPLANT OUTCOMES	C21949467	—	24,581
93.839	MACHINE LEARNING WITH IMMUNOGENETICS FOR THE PREDICTION OF HEMATOPOIETIC CELL TRANSPLANT OUTCOMES	C22269254	—	22,038
93.855	PROJECT 1: ANTIVIRAL TARGETING TO SUPPRESS DRUG RESISTANCE	MSKSUB00000093	—	47,031
93.353	THE MSKCC-UW/FRED HUTCH PROSTATE CANCER DRUG RESISTANCE AND SENSITIVITY CENTER	C21868065	—	(253)
	ST JUDE CHILDRENS RESEARCH HOSPITAL:			
93.395	CHILDHOOD CANCER SURVIVOR STUDY	11128728A-8084348	—	216,167
93.395	CHILDHOOD CANCER SURVIVOR STUDY	11128728E-8084348	—	12,697
93.395	CHILDHOOD CANCER SURVIVOR STUDY	11128729E-8138615	—	11,437
93.395	CHILDHOOD CANCER SURVIVORSHIP STUDY	11128729A-8138353	—	436,370
93.853	CULTURALLY ADAPTED MOBILE TREATMENT OF CHRONIC PAIN IN ADOLESCENT SURVIVORS OF PEDIATRIC BONE SARCOMA	11322601D-8149851	—	11,437
93.855	DECODING THE INTERACTIONS BETWEEN T CELL RECEPTORS AND PEPTIDE-MHC	112404050-8088994	—	152,723
93.394	EHEALTH INTERVENTION FOR LATE EFFECTS OF CHILDHOOD CANCER	11253903B	—	13,651
93.394	EHEALTH INTERVENTION FOR LATE EFFECTS OF CHILDHOOD CANCER	AWOA	—	23,749
	STANFORD UNIVERSITY:			
93.855	A VACCINE DESIGN TO INDUCE PROTECTIVE B AND T CELL IMMUNITY AGAINST HEPATITIS C VIRUS	62918007-192167	—	84,086
93.855	EPIGENETIC HISTONE LANDSCAPE PROFILES IN HIV	62954422-248882	—	9,332
93.837	THE WHI STRONG AND HEALTHY SILENT ATRIAL FIBRILLATION RECORDING STUDY (WHISH STAR)	61526612-125216	—	(7,095)
93.837	THE WHI STRONG AND HEALTHY SILENT ATRIAL FIBRILLATION RECORDING STUDY (WHISH STAR)	62990566-125216	—	17,988
93.837	TRANS-OMICS ELUCIDATION OF GENETIC ARCHITECTURE UNDERLYING CARDIOVASCULAR & OTHER COMPLEX DISEASES	62070755-131760	—	1,998
	SWEDISH MEDICAL CENTER:			
93.399	THE PACIFIC CANCER RESEARCH CONSORTIUM (PCRC) NCORP, A COMMUNITY SITE	10009523-FH	—	29,023
93.399	THE PACIFIC CANCER RESEARCH CONSORTIUM (PCRC) NCORP, A COMMUNITY SITE	907015 C.08	—	4,801
	TALUS BIOSCIENCE:			
93.350	ILLUMINATING THE DARK KINASES - EFFECTS ON PROTEOME TRANSLOCATION AND CHROMATIN BINDING	NA	—	88,000
	THE EMMES COMPANY, LLC:			
93.395	AIDS MALIGNANCY CONSORTIUM (AMC)	NA	—	13,717
93.395	THE AIDS MALIGNANCY CONSORTIUM GRANT	13765	—	31,405

FRED HUTCHINSON CANCER CENTER
Schedule of Expenditures of Federal Awards
Year ended June 30, 2023

Federal ALN or Grant	Pass-through Funds – Department of Health and Human Services and Other Federal Agencies	Passed-through entity or award identifying number	Passed-through to subrecipients	Expenditures
			\$	
93.395	THE GEORGE WASHINGTON UNIVERSITY: AIDS AND CANCER SPECIMEN RESOURCE: IDENTIFYING PREDICTORS OF KAPOSI SARCOMA IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME	21-M41	—	113
12.U03	THE J. DAVID GLADSTONE INSTITUTES: ANIMAL TESTING OF TIPS: A SINGLE ADMINISTRATION ESCAPE-RESISTANT HIV ANTIVIRAL THERAPY	SC-00029	—	131,289
93.393	THE REGENTS OF UNIVERSITY OF MICHIGAN: ACTIVE SYMPTOM MONITORING AND ENDOCRINE THERAPY PERSISTENCE IN YOUNG WOMEN WITH BREAST CANCER	SUBK00014900	—	22,844
93.393	DEVELOPMENT OF AN INTEGRATED RISK PREDICTION MODEL OF TAXANE-INDUCED PERIPHERAL NEUROPATHY	SUBK00016888	—	13,637
93.838	PARAMETRIC RESPONSE MAPPING (PRM) FOR THE DETECTION OF CHRONIC LUNG INJURY IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS	SUBK00015626	—	2,542
93.393	THE RESEARCH FOUNDATION OF SUNY: MS. LILAC: MUSCLE MASS IN THE LIFE AND LONGEVITY AFTER CANCER (LILAC) STUDY	R1358563	—	33,656
93.855	THE ROCKEFELLER UNIVERSITY: DEFINING THE MECHANISMS OF HIV RESISTANCE TO BNABS IN HUMANS	SUB00000271	—	73,652
93.855	DEFINING THE MECHANISMS OF HIV RESISTANCE TO BNABS IN HUMANS	SUB00000272	—	182,412
93.855	DEFINING THE MECHANISMS OF HIV RESISTANCE TO BNABS IN HUMANS	SUB00000361	—	30,024
93.855	THE SCRIPPS RESEARCH INSTITUTE: CONSORTIUM FOR HIV/AIDS VACCINE DEVELOPMENT	5-54557	—	(4,075)
93.855	CONSORTIUM FOR HIV/AIDS VACCINE DEVELOPMENT	5-54563	—	17,641
93.855	CONSORTIUM FOR HIV/AIDS VACCINE DEVELOPMENT	5-54884	—	470,042
93.855	CONSORTIUM FOR HIV/AIDS VACCINE DEVELOPMENT	5-54890	—	269,233
93.855	CONSORTIUM FOR HIV/AIDS VACCINE DEVELOPMENT: DATA MANAGEMENT SRSU	5-54552	—	(497)
93.855	CONSORTIUM FOR HIV/AIDS VACCINE DEVELOPMENT: DATA MANAGEMENT SRSU	5-54879	—	67,573
93.394	THE UNIVERSITY OF TEXAS: (0007046) CIRCULATING BIOMARKERS AND IMAGING FOR EARLY DETECTION OF PANCREATIC CANCER	3001914918	—	1,028
93.394	CLINICAL VALIDATION CENTER FOR LUNG CANCER EARLY DETECTION	3002045740	—	21,841
93.847	CONSORTIUM FOR THE STUDY OF CHRONIC PANCREATIC, DIABETES AND PANCREATIC CANCER COORDINATING AND DATA MANAGEMENT CENTER (CSCPDPCC-CDMC)	3001641895	—	7,698
93.847	CONSORTIUM FOR THE STUDY OF CHRONIC PANCREATIC, DIABETES AND PANCREATIC CANCER COORDINATING AND DATA MANAGEMENT CENTER (CSCPDPCC-CDMC)	3002023052	—	686,469
93.393	DEVELOPMENT OF RISK AND EARLY DETECTION BIOMARKER FOR SMALL CELL LUNG CANCER	3001871804	—	13,610
93.855	THE WISTAR INSTITUTE: BEAT-HIV: DELANEY COLLABORATORY TO CURE HIV-1 INFECTION BY COMBINATION IMMUNOTHERAPY	25902-72-324	—	51,821
93.855	BEAT-HIV: DELANEY COLLABORATORY TO CURE HIV-1 INFECTION BY COMBINATION IMMUNOTHERAPY	25901-72-324	—	179,205
93.855	TUFTS UNIVERSITY: STRUCTURE, ANTIGENICITY, AND FUNCTION OF HCMV FUSOGEN GB	103889-00001	—	239,868
93.855	TULANE UNIVERSITY: ROLE OF RHC MV IN SHAPING THE SIV PROVIRAL LANDSCAPE	TUL-HSC-559982-21/22	—	4,426
93.855	USING PARENTERAL COMBINATION ADJUVANTS TO INDUCE PAN-MUCOSAL CELLULAR AND HUMORAL IMMUNITY	TUL-HSC-560378-22/23	—	38,119
93.213	UNIVERSITY OF ALABAMA: ASSESSING PSYCHOLOGICAL FINANCIAL BURDEN IN CANCER	000528180-SC002	—	29,361
93.855	DEFINING THE BIOLOGICAL RELEVANCE OF HIV-1 ADAPTATION TO CD4 T CELL RESPONSES	000515868-001	—	48,226
93.393	UNIVERSITY OF ARIZONA: ROLE OF FSH IN POSTMENOPAUSAL OBESITY AND BREAST CANCER	649976	—	95,671
93.866	THYMIC AND PERIPHERAL ASPECTS OF T CELL AGING AND REJUVENATION	413308	—	6,049
93.855	UNIVERSITY OF CALIFORNIA LOS ANGELES: (ATTACK)2: GENETIC ENGINEERING OF CELLULAR AND HUMORAL IMMUNITY TO CURE HIV: NHP CORE	1559 G XG089	—	439,318
93.855	(ATTACK)2: GENETIC ENGINEERING OF CELLULAR AND HUMORAL IMMUNITY TO CURE HIV: NHP CORE	AWOA	—	66,649
93.397	UCLA SPORE IN PROSTATE CANCER	2301 G XE827	—	15,820
93.866	UNIVERSITY OF CALIFORNIA, SAN DIEGO: EPIGENETIC AGING BIOMARKERS OF MILD COGNITIVE IMPAIRMENT, ALZHEIMER'S DISEASE AND RELATED DEMENTIAS, AND BRAIN AGING	KR 704683	—	251,224
93.837	OBJECTIVE PHYSICAL ACTIVITY AND CARDIOVASCULAR HEALTH IN OLDER WOMEN: OPACH2	KR 705637	—	43,217
93.866	PLASMA PROTEOMIC SIGNATURES FOR ALZHEIMER'S DISEASE AND RELATED DEMENTIAS	705689	—	37,870
93.866	SEDENTARY BEHAVIOR INTERRUPTED: ACUTE, MEDIUM AND LONG-TERM EFFECTS ON BIOMARKERS OF HEALTHY AGING, PHYSICAL FUNCTION AND MORTALITY	98047373	—	44,173
93.855	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO: DELANEY AIDS RESEARCH ENTERPRISE TO CURE HIV	13661SC	—	195,952
93.855	DELANEY AIDS RESEARCH ENTERPRISE TO CURE HIV	AWOA	—	16,097
93.859	HARC CENTER COLLABORATIVE OPPORTUNITY FUND	13084SC	—	53,258
93.859	HARC CENTER: HIV ACCESSORY AND REGULATORY COMPLEXES: PROJECT 7: CHARACTERIZATION OF SUPER RESTRICTION FACTORS AND PREDICTION OF HOST-HIV INTERFACES	10368SC	—	144,976
93.855	HARC: HIV ACCESSORY AND REGULATORY COMPLEXES	13896SC	—	149,471
93.855	HARC: HIV ACCESSORY AND REGULATORY COMPLEXES	13900SC	—	492,023
93.855	HARC: HIV ACCESSORY AND REGULATORY COMPLEXES	AWOA	—	18,952
93.855	TARGETING HIV-SPECIFIC T CELL DIFFERENTIATION PROGRAMS TO ENHANCE POST-TREATMENT CONTROL OF HIV	13383SC	—	19,899
93.855	THE HETEROGENEOUS HIV EXPRESSING RESERVOIR: DYNAMICS, PERSISTENCE MECHANISMS, TISSUE DISTRIBUTION, AND CONTRIBUTION TO REBOUND	13614SC	—	29,027
93.855	UNIVERSITY OF CAPE TOWN: ANTIGENIC AND VIROLOGICAL TRAITS OF HIV-1 BREAKTHROUGH INFECTIONS IN THE VRC01 ANTIBODY-MEDIATED PREVENTION PHASE 2B TRIAL IN SUB-SAHARAN AFRICA	UCT00033668	—	61,423

FRED HUTCHINSON CANCER CENTER
Schedule of Expenditures of Federal Awards
Year ended June 30, 2023

Federal ALN or Grant	Pass-through Funds – Department of Health and Human Services and Other Federal Agencies	Passed-through entity or award identifying number	Passed-through to subrecipients	Expenditures
93.855	DURABILITY OF SYSTEMIC AND LUNG IMMUNE CORRELATES OF BCG-INDUCED PROTECTION AGAINST M. TUBERCULOSIS INFECTION UNIVERSITY OF CHICAGO:	UCT00033560	\$ —	29,201
12.420	TRNA MEDIATED REGULATION OF PROSTATE CANCER BIOLOGY UNIVERSITY OF CINCINNATI:	AWD102961(SUB00000754)	—	101,476
93.395	PILOT 3: ITSC FOR LEUKEMIA: NOVEL MOLECULAR STRATEGIES FOR NCTN INDIVIDUALIZED THERAPIES	013711-00002	—	187,402
93.395	PILOT 3: ITSC FOR LEUKEMIA: NOVEL MOLECULAR STRATEGIES FOR NCTN INDIVIDUALIZED THERAPIES	AWOA	—	(53,662)
93.395	SLC: ITSC FOR LEUKEMIA: NOVEL MOLECULAR STRATEGIES FOR NCTN: "INDIVIDUALIZED" THERAPIES	AWOA	—	(10,754)
93.395	SLC: ITSC FOR LEUKEMIA: NOVEL MOLECULAR STRATEGIES FOR NCTN: "INDIVIDUALIZED" THERAPIES	AWOA	—	(9,936)
93.855	UNIVERSITY OF FLORIDA: MATHEMATICAL AND STATISTICAL METHODS FOR THE CONTROL OF GLOBAL INFECTIOUS DISEASE THREATS	SUB000002465	—	31,463
93.393	UNIVERSITY OF HAWAII: EFFECTS OF INTERMITTENT ENERGY RESTRICTION ON INTRA-ABDOMINAL FAT AND THE GUT MICROBIOME: A RANDOMIZED TRIAL	KA1759	—	97,531
93.307	LONGITUDINAL STUDY OF EARLY NAFLD PROGRESSION AND THE GUT MICROBIOME IN ASIAN AMERICANS, NATIVE HAWAIIANS AND WHITES	KA1907	—	41,848
93.855	UNIVERSITY OF MARYLAND, BALTIMORE: IMPLEMENTING VACCINE AND TREATMENT VALUATION (VTEU) CLINICAL SITE PROTOCOLS; COVPPN 3004 NOVAVAX SNIFF - COVID-19	20687	—	82,099
93.855	NOVAVAX SNIFF SUBSTUDY (3004-01)	20687	—	70,309
93.847	UNIVERSITY OF MASSACHUSETTS MEDICAL SCH: IPAT: INTELLIGENT DIET QUALITY PATTERN ANALYSIS FOR HARMONIZED MA-NATIONAL TRIALS	FANG-34658-FHCC	—	14,941
93.393	UNIVERSITY OF MELBOURNE: COLON CANCER FAMILY REGISTRY COHORT	GL058179-FH-Y5	—	606,023
93.393	THE COLON CANCER FAMILY REGISTRY COHORT	GL058179-FH-Y6	—	98,881
12.420	UNIVERSITY OF MINNESOTA: IMPACT OF PLATINUM RELATED HEARING LOSS ON QUALITY OF LIFE AND EDUCATIONAL ATTAINMENT IN GERM CELL TUMOR SURVIVORS	N009613402	—	19,608
93.839	IMPLICATIONS OF PARP1 IN MYELODYSPLASTIC SYNDROMES AND TARGETED THERAPY	P009464001	—	130,832
93.865	OPTIMIZING IMMUNITY AND MATERNAL HOST DEFENSE AGAINST CONGENITAL CYTOMEGALOVIRUS INFECTION	N007639103	—	161,011
93.865	OPTIMIZING IMMUNITY AND MATERNAL HOST DEFENSE AGAINST CONGENITAL CYTOMEGALOVIRUS INFECTION	N007639101	—	(12,426)
93.393	ROLE OF GENETIC AND EPIGENETIC ALTERATIONS IN CFTR IN COLORECTAL CANCER	N009056002	—	22,996
93.855	UNIVERSITY OF NEW MEXICO: VIRUS-LIKE PARTICLE BASED MALARIA VACCINES TARGETING VULNERABLE EPITOPES IN THE CIRCUMSPOROZOITE PROTEIN	3RPF5	—	98,815
93.855	UNIVERSITY OF NORTH CAROLINA CHAPEL HILL: CAUSAL INFERENCE IN INFETIOUS DISEASE PREVENTION STUDIES	5117932	—	65,235
93.867	CHARACTERIZING VISION IMPAIRMENT AND ITS IMPACT ON INDEPENDENCE IN OLDER ADULTS	5127550	—	25,408
93.855	COLLABORATORY OF AIDS RESEARCHERS FOR ERADICATION (CARE)	5124533	—	121,709
93.855	COLLABORATORY OF AIDS RESEARCHERS FOR ERADICATION (CARE)	5128352	—	17,324
93.393	PHYSICAL ACTIVITY, SEDENTARY BEHAVIOR, AND CANCER INCIDENCE IN WOMEN	5115809	—	72,729
93.172	POLYGENIC RISK SCORES AND HEALTH DISPARITIES: THE ROLE OF BLOOD CELLS IMMUNE RESPONSE AND EVOLUTIONARY ADAPTATION	5124208	—	87,865
93.172	POLYGENIC RISK SCORES AND HEALTH DISPARITIES: THE ROLE OF BLOOD CELLS IMMUNE RESPONSE AND EVOLUTIONARY ADAPTATION	5127820	—	27,209
93.855	SYSTEMS IMMUNOGENETICS OF BIODEFENSE AND EMERGING PATHOGENS IN THE COLLABORATIVE CROSS	5122354	—	7,662
93.307	THE VAGINAL MICROBIOME AND RACIAL DISPARITY IN PRETERM DELIVERY	5106998	—	14,575
93.855	UNIVERSITY OF PENNSYLVANIA: ENGINEERING T CELLS TO PROVIDE DURABLE CONTROL OF HIV-1 REPLICATION	584707	—	353,735
93.U26	NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND REPNSE	584518	—	351,419
93.U27	NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE	586796	—	95,771
93.U25	NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE PENN-CEIRR OPTION 19 A (PRISM LINE 6)	57558	—	106,578
93.393	POST GENOME-WIDE ASSOCIATION STUDIES IN TESTICULAR GERM CELL TUMORS	583406	—	1,394
93.393	POST GENOME-WIDE ASSOCIATION STUDIES IN TESTICULAR GERM CELL TUMORS	586004	—	19,058
93.859	UNIVERSITY OF PITTSBURGH: MIDAS COORDINATION CENTER	AWD00000238 (136372-1)	—	52,744
93.855	PROSPECTIVE EPIDEMIOLOGIC STUDY OF NOVEL ETIOLOGIC AGENTS OF PELVIC INFLAMMATORY DISEASE	AWD00002682 (134944-1)	—	516,621
93.866	SLEEP, FALLS AND FRACTURES IN MEN AND WOMEN: ROLE OF NOCTURNAL HYPOXIA	AWD00001899 (137160-2)	—	152,395
93.279	UNIVERSITY OF RHODE ISLAND: CAUSAL INFERENCE METHODS FOR HIV PREVENTION STUDIES AMONG NETWORKS OF PEOPLE WHO USE DRUGS	0006817/08152018	—	11,358
93.855	UNIVERSITY OF ROCHESTER: MODELING MECHANISMS OF ADJUVANTED INFLUENZA VACCINE INDUCED IGG REPERTOIRE DIVERSITY AND HETEROSUBTYPIC IMMUNITY URF (AWD00001405)	417029-G/URFAOGR510616	—	72,377
93.847	UNIVERSITY OF SOUTH CAROLINA: IMPACT OF DISPARITIES IN FOOD SECURITY ON GLYCEMIC CONTROL AND HEALTH CARE UTILIZATION AMONG YOUTH AND YOUNG ADULTS WITH DIABETES	23-5339	—	17,498
93.393	UNIVERSITY OF SOUTHERN CALIFORNIA: AN INTEGRATIVE MULTI-OMICS APPROACH TO CHARACTERIZE PROSTATE CACER RISK IN DIVERSE POPULATIONS	SCON-00003751	—	15,849
93.393	AN INTEGRATIVE MULTI-OMICS APPROACH TO CHARACTERIZE PROSTATE CANCER RISK IN DIVERSE POPULATIONS	SCON-00003044	—	(8)
93.393	DETERMINANTS OF THE RACIAL/ETHNIC DISPARITY IN MGUS RISK: AN EPIDEMIOLOGIC STUDY IN 4 COHORTS	2021-1592	—	66,064
93.393	LEVERAGING DIVERSITY IN CANCER EPIDEMIOLOGY COHORT	SCON-00003752	—	92,005
93.U29	LEVERAGING DIVERSITY IN CANCER EPIDEMIOLOGY COHORTS AND NOVEL METHODS TO IMPROVE POLYGENIC RISK SCORES	AWOA	—	4,050
93.839	NOVEL HEMATOPOIETIC STEM CELL ENGINEERING AND TRANSPLANTATION APPROACHES FOR HIV CURE	133295422	—	(267,099)
93.839	NOVEL HEMATOPOIETIC STEM CELL ENGINEERING AND TRANSPLANTATION APPROACHES FOR HIV CURE	AWOA	—	130,549
93.839	NOVEL HEMATOPOIETIC STEM CELL ENGINEERING AND TRANSPLANTATION APPROACHES FOR HIV CURE	SCON-00003661	—	590,549
93.847	NOVEL HEMATOPOIETIC STEM CELL ENGINEERING AND TRANSPLANTATION APPROACHES FOR HIV CURE	SCON-00003661	—	267,297

FRED HUTCHINSON CANCER CENTER
Schedule of Expenditures of Federal Awards
Year ended June 30, 2023

Federal ALN or Grant	Pass-through Funds – Department of Health and Human Services and Other Federal Agencies	Passed-through entity or award identifying number	Passed-through to subrecipients	Expenditures
12.420	UNIVERSITY OF SYDNEY: ASPIRIN AND NSAID USE AND OVARIAN CANCER PROGNOSIS (AS678)	G214239	\$ —	84,962
93.855	UNIVERSITY OF TEXAS HSC AT SAN ANTONIO: DEFINING CONSERVED EPITOPES ON POLYMORPHIC MALARIA ANTIGENS	169189/169185	—	65,111
93.393	UNIVERSITY OF UTAH: CHANGING CONTRACEPTIVE PATTERNS AND OVARIAN CANCER RISK	10057578-01-FRED	—	8,689
93.847	HEMATOLOGY CENTRAL COORDINATING CENTER (HCCC)	1005584-01	—	9,017
93.847	HEMATOLOGY CENTRAL COORDINATING CENTER (HCCC) FOR THE NIDDK HEMATOLOGY CENTERS PROGRAM	1005584-01	—	69,542
93.393	IDENTIFYING CANCER RECURRENCE WITH NOVEL DATA LINKAGES WITH A CANCER REGISTRY	10063551-02-FHCR	—	46,750
93.393	METABOLOMIC STRATEGIES FOR DISCOVERY AND VALIDATION OF BIOMARKERS OF COLORECTAL CANCER RECURRENCE	10043057-01	—	302,452
93.393	TRANSDISCIPLINARY TEAM SCIENCE IN COLORECTAL CANCER PROGNOSIS: THE COLOCARE STUDY	10059766-04	—	245,382
93.394	UNIVERSITY OF WASHINGTON: A QUANTITATIVE PET/CT RESEARCH RESOURCE FOR CO-CLINICAL IMAGING OF LUNG CANCER THERAPIES	UWSC13793	—	225,604
93.396	ACTIVATION OF THE DNA-PK-DEPENDENT ANTIVIRAL RESPONSE AS A NOVEL CANCER IMMUNOTHERAPY	UWSC13556	—	319,372
93.121	AN INTEGRATED FIBER-MICRONEEDLE DEVICE TO STUDY AND OPTIMIZE IMMUNE RESPONSES	UWSC14479	—	14,828
93.279	ANTIBODY-BASED COUNTERMEASURES AGAINST FENTANYL AND ITS ANALOGUES	AWOA	—	(48,398)
93.279	ANTIBODY-BASED COUNTERMEASURES AGAINST FENTANYL AND ITS ANALOGUES	UWSC13713	—	109,022
93.393	BACTERIAL CORRELATES OF COLORECTAL CANCER SUBTYPES AND SURVIVAL	UWSC14230	—	403,893
93.395	BIOMARKERS OF RESPONSE TO IMMUNO-CHEMOTHERAPY AND OLIGOMETASTATIC HYPOFRACTIONATED RADIOTHERAPY (BRIGHT) FOR LUNG CANCER: SYNERGY OF PET/CT IMAGING AND PERIPHERAL BLOOD ASSAYS	UWSC13903	—	36,478
12.420	BOOSTING COMPLEMENT ACTIVITY SUPPRESSES DEVELOPMENT OF CASTRATION RESISTANCE	UWSC14184	—	51,585
93.855	CENTER FOR AIDS RESEARCH (CFAR): CORE 1 - IMMUNOLOGY CORE - YR 34	UWSC13698	—	3,527
93.855	CENTER FOR AIDS RESEARCH (CFAR): CORE 1 - IMMUNOLOGY CORE - YR 35	UWSC13698	—	115,305
93.U30	CFAR - ADMINISTRATIVE CORE	AWOA	—	1,167
93.855	CFAR AIDS-ASSOCIATED INFECTIONS AND MALIGNANCIES CORE	UWSC10495	—	(54,345)
93.855	CFAR AIDS-ASSOCIATED INFECTIONS AND MALIGNANCIES CORE	UWSC13796	—	54,039
93.855	CFAR AIDS-ASSOCIATED INFECTIONS AND MALIGNANCIES CORE -- YEAR 35	UWSC13796	—	202,437
93.855	CFAR NEW INVESTIGATOR AWARD: VALIDATION OF A NOVEL RAPID URINE-BASED DIAGNOSTIC ASSAY FOR TUBERCULOSIS IN SOUTH AFRICA	UWSC14366	—	15,937
93.855	CURATIVE THERAPIES FOR HIV SCIENTIFIC WORKING GROUP	UWSC13699	—	35,407
93.855	CYTOMEGALOVIRUS (CMV) VACCINE IN ORTHOTOPIC LIVER TRANSPLANT CANDIDATES ("COLT")	UWSC13718	—	255
93.855	CYTOMEGALOVIRUS (CMV) VACCINE IN ORTHOTOPIC LIVER TRANSPLANT CANDIDATES (COLT)	AWOA	—	5,950
93.855	CYTOMEGALOVIRUS (CMV) VACCINE IN ORTHOTOPIC LIVER TRANSPLANT CANDIDATES (COLT)	UWSC13718	—	68,041
93.859	DECIPHERING THE ROLE OF CHEMICAL SIGNALS IN INFLAMMATION WITH OPENMICROFLUIDIC FUNCTIONAL ASSAY	UWSC14072	—	73,547
93.353	DEVELOPING A RIDE-SHARE INTERVENTION TO IMPROVE FOLLOW-UP OF ABNORMAL FECAL IMMUNOCHEMICAL TEST (FIT) RESULTS	UWSC12681	—	(13,514)
93.353	DEVELOPING A RIDE-SHARE INTERVENTION TO IMPROVE FOLLOW-UP OF ABNORMAL FECAL IMMUNOCHEMICAL TEST (FIT) RESULTS	UWSC14000	—	38,879
93.398	DEVELOPING DATA-DRIVEN CANCER RESEARCHERS	UWSC14660	—	13,402
93.395	DIFFERENTIAL RESPONSE OF GLIOBLASTOMAS TO MICROTUBULE TARGETIG AGENTS	UWSC13783	—	29,533
93.396	DIGITAL PCR QUANTIFICATION OF BCR-ABL FOR CML DIAGNOSIS AND MONITORING IN A LMICS SETTING	UWSC13952	—	41,158
93.855	DRUG-ELUTING FIBERS FOR ON-DEMAND AND EXTENDED PROTECTION AGAINST HIV	UWSC13777	—	51,927
93.172	EMERGE IV NORTHWEST: A PARTNERSHIP TO EVALUATE THE USE OF GENOMIC INFORMATION IN THE HEALTH CARE OF DIVERSE PARTICIPANTS	NA	—	(3,000)
93.U31	EMERGE IV NORTHWEST: A PARTNERSHIP TO EVALUATE THE USE OF GENOMIC INFORMATION IN THE HEALTH CARE OF DIVERSE PARTICIPANTS	AWOA	—	3,111
93.172	EMERGE IV NORTHWEST: A PARTNERSHIP TO EVALUATE THE USE OF GENOMIC INFORMATION IN THE HEALTH CARE OF DIVERSE PARTICIPANTS	UWSC14191	—	14,288
93.350	ENGINEERING ADOPTIVE T CELL THERAPY TO OVERCOME FAS-MEDIATED CELL DEATH IN OVARIAN CANCER	AWOA	—	(6,885)
93.865	ENHANCING PREP OUTCOMES AMONG KENYAN ADOLESCENT GIRLS AND YOUNG WOMEN WITH A NOVEL PHARMACY-BASED PREP DELIVERY PLATFORM	UWSC13859	—	7,170
93.855	EVALUATING THE RELATIONSHIP OF CD101 AND UBE2V1 TO GENITAL MUCOSAL INFLAMMATION	UWSC10291	—	255,914
93.U32	GENETICS OF ZEBRAFISH HAIR CELL TOXICITY	AWOA	—	2,333
93.173	GENETICS OF ZEBRAFISH HAIR CELL TOXICITY	UWSC13757	—	44,174
93.067	GH16-1629 HIV SURVEILLANCE FOR EPIDEMIC CONTROL IN MALAWI UNDER THE PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF	UWSC13708	—	8,435
93.394	HIGH-CONTENT FUNCTIONAL CANCER DRUG TESTING ON MICRO-CUBOIDAL TUMOR DISSECTIONS	UWSC12178	—	232
93.394	HIGH-CONTENT FUNCTIONAL CANCER DRUG TESTING ON MICRO-CUBOIDAL TUMOR DISSECTIONS	UWSC13977	—	28,159
93.855	HSV-2 SPECIFICITY AND PHENOTYPING OF TISSUE-BASED T CELLS IN GENITAL SKIN BIOPSIES OF HSV-2 REACTIVATION	AWOA	—	3,542
93.855	HSV-2 SPECIFICITY AND PHENOTYPING OF TISSUE-BASED T CELLS IN GENITAL SKIN BIOPSIES OF HSV-2 REACTIVATION	UWSC14561	—	43,254
93.395	IMMUNOBIOLOGY AND IMMUNE THERAPY FOR MERKEL CELL CARCINOMA	AWOA	—	52,311
93.395	IMMUNOBIOLOGY AND IMMUNE THERAPY FOR MERKEL CELL CARCINOMA	UWSC13818	—	1,262,668
93.395	IMMUNOBIOLOGY AND IMMUNE THERAPY FOR MERKEL CELL CARCINOMA	UWSC13831	—	205,682
93.395	IMMUNOBIOLOGY AND IMMUNE THERAPY FOR MERKEL CELL CARCINOMA/CORE 3: BIOSTATISTICS AND BIOINFORMATICS	UWSC13830	—	376,829
93.395	IMMUNOLOGY AND IMMUNE THERAPY FOR MERKEL CELL CARINCOMA	UWSC13829	—	145,118
93.865	IMPACT OF PERICONCEPTUAL VAGINAL MICROBIOTA ON WOMENS RISK OF PRETERM BIRTH	UWSC9487	—	10,331
93.397	IMPROVING IDENTIFICATION OF DETERMINANTS OF EVIDENCE-BASED PRACTICE IMPLEMENTATION	UWSC13797	—	35,182
93.855	IN VIVO HSC GENE THERAPY USING A MULTI-MODULAR HDAD VECTOR FOR HIV CURE	UWSC14471	—	27,129
93.865	INFANT IMMUNE MECHANISMS OF HIV RESERVOIR SIZE AND DECAY	UWSC13770	—	309,512
93.855	INJECTABLE HYDROGEL DEPOTS FOR SELF-REPLICATING MRNA VACCINE DELIVERY	UWSC13983	—	6,428
93.350	INSTITUTE FOR TRANSLATIONAL HEALTH SCIENCES (ITHS)	NA	—	(26,748)
93.350	INSTITUTE FOR TRANSLATIONAL HEALTH SCIENCES (ITHS)	UWSC13474	—	252,459
93.350	INSTITUTE OF TRANSLATIONAL HEALTH SCIENCES (ITHS)	UWSC13474	—	110,719
93.395	INTERROGATING THE RESPONSE OF THE TUMOR MICROENVIRONMENT TO COMBINATION IMMUNOTHERAPY USING A MICROFLUIDIC PLATFORM	UWSC13883	—	180,523
93.847	INVESTIGATION OF MEDICAL MANAGEMENT TO PREVENT EPISODES OF DIVERTICULITIS (IMPEDE) TRIAL	UWSC14035	—	20,243

FRED HUTCHINSON CANCER CENTER
Schedule of Expenditures of Federal Awards
Year ended June 30, 2023

Federal ALN or Grant	Pass-through Funds – Department of Health and Human Services and Other Federal Agencies	Passed-through entity or award identifying number	Passed-through to subrecipients	Expenditures
93.172	ITGS: POSTDOCTORAL TRAINEE: J. FATHERREE	UWSC13940	\$ —	64,331
93.396	JOINT RECEPTOR AND PROTEIN EXPRESSION IMMUNOPHENOTYPING THROUGH SPLIT-POOL BARCODING	UWSC14467	—	194,547
93.394	LARGE SCALE CLINICAL AND ECONOMIC IMPACT ANALYSIS OF POTENTIALLY MALIGNANT INCIDENTAL FINDINGS IN RADIOLOGY REPORTS	UWSC13588	—	13,135
12.420	LIGHT-SHEET MICROSCOPY: IDENTIFICATION AND MOLECULAR CHARACTERIZATION OF PROSTATE CARCINOMA WITH DE NOVO RESISTANT TO TOTAL ANDROGEN ABLATIVE THERAPY			
93.399	LIVER CANCER DISPARITIES IN ALASKA NATIVE AND AMERICAN INDIAN PEOPLE	UWSC14339	—	56,732
93.399	LIVER CANCER DISPARITIES IN ALASKA NATIVE AND AMERICAN INDIAN PEOPLE	UWSC14228	—	204,122
93.838	LUNG TRANSPLANT RECIPIENT EXOSOME PHENOTYPES AND THE RISK OF PRIMARY GRAFT DYSFUNCTION AND ACUTE LUNG ALLOGRAFT DYSFUNCTION	UWSC14266	—	70,089
93.855	MALARIA EVOLUTION IN SOUTH ASIA	UWSC14408	—	14,297
47.049	MF8: DEEP-LEARNING ENABLED STRUCTURE PREDICTION AND DESIGN OF PROTEIN-DNA ASSEMBLIES	UWSC13673	—	48,317
93.855	MODELING OF HUMAN HSV INFECTION: DEVELOPMENT OF 3D SKIN-ON-CHIP WITH VASCULAR PERFUSION	UWSC14099	—	114,059
93.394	MULTIPLEXED DRUG TESTING OF MICRO-DISSECTED TUMORS USING A MICROFLUIDIC PLATFORM WITH INTEGRATED ELECTROCHEMICAL APTASENSORS	UWSC13630	—	138,778
93.855	NEXTGEN LONG-ACTING PLATFORM: TARGETED COMBINATION ANTIRETROVIRALS	UWSC14640	—	18,088
93.859	NOVEL STATISTICAL INFERENCE FOR BIOMEDICAL BIG DATA	UWSC14458	—	5,804
93.847	NUTRITION OBESITY RESEARCH CENTER	UWSC13647	—	35,192
93.397	OPTIMIZING IMPLEMENTATION IN CANCER CONTROL: OPTICC	UWSC13849	—	109,871
93.865	PEDIATRIC HIV RESERVOIR DETERMINANTS AND CONSEQUENCES	UWSC13826	—	14,504
93.839	POSTDOCTORAL FELLOW: ADAM HECK - HEMATOLOGY TRAINING	UWSC13981	—	64,113
93.398	POSTDOCTORAL FELLOW: BRAD KRAJINA	UWSC13738	—	59,971
93.398	POSTDOCTORAL FELLOW: BRAD KRAJINA	UWSC13916	—	26,874
93.398	POSTDOCTORAL FELLOW: CLAIRE THOMAS - CANCER PREVENTION TRAINING: EPIDEMIOLOGY, NUTRITION, GENETICS AND SURVIVORSHIP	UWSC13916	—	40,383
93.398	POSTDOCTORAL FELLOW: COLETTE DAVIS - CANCER PREVENTION TRAINING: EPIDEMIOLOGY, NUTRITION, GENETICS AND SURVIVORSHIP	UWSC14216	—	58,326
93.398	POSTDOCTORAL FELLOW: DARYA MOOSAVI - UW T32 SUBAWARD	UWSC14367	—	57,886
93.989	POSTDOCTORAL FELLOW: ELIZABETH GULLEEN - NORTHERN/PACIFIC UNIVERSITIES GLOBAL HEALTH RESEARCH TRAINING CONSORTIUM	UWSC14507	—	31,420
93.398	POSTDOCTORAL FELLOW: HANNAH ARBACH - INVESTIGATING NUCLEAR ENVELOPE VULNERABILITIES USING VIRAL SYSTEMS	UWSC14390	—	4,743
93.855	POSTDOCTORAL FELLOW: KATHERINE RACHAEL PARKS	UWSC14328	—	22,028
93.855	POSTDOCTORAL FELLOW: KRISTI GEIGER STD AND AIDS RESEARCH TRAINING GRANT	UWSC12847	—	29,543
93.172	POSTDOCTORAL FELLOW: MATTHEW WOOTEN - INTERDISCIPLINARY TRAINING IN GENOME SCIENCES	UWSC13589	—	28,072
93.398	POSTDOCTORAL FELLOW: NAMITA HATTANGADY - INTERDISCIPLINARY TRAINING IN CANCER RESEARCH	UWSC13822	—	66,275
93.398	POSTDOCTORAL FELLOW: NAMITA HATTANGADY - UW T32 INTERDISCIPLINARY TRAINING IN CANCER RESEARCH	UWSC13882	—	31,276
93.398	POSTDOCTORAL FELLOW: NATALIE DEL VECCHIO - CANCER PREVENTION TRAINING: EPIDEMIOLOGY, NUTRITION, GENETICS & SURVIVORSHIP	UWSC13882	—	46,489
93.855	POSTDOCTORAL FELLOW: QING YANG UW T32 SUBAWARD	AWOA	—	5,469
93.855	POSTDOCTORAL FELLOW: SARAH VICK - DISEASE OF PUBLIC HEALTH IMPORTANCE TRAINING GRANT	UWSC13614	—	50,143
93.855	PREP AND DPPEP: DOXYCYCLINE POST-EXPOSURE PROPHYLAXIS FOR PREVENTION OF SEXUALLY TRANSMITTED INFECTIONS AMONG KENYAN WOMEN USING HIV PRE-EXPOSURE PROPHYLAXIS			
93.855	PROJECT 3: MECHANISMS OF IMMUNE ACTIVATION, INFLAMMATION AND NEURODEVELOPMENT IN CHILDREN EXPOSED TO HIV INFECTION	UWSC14359	—	6,245
93.859	PROTEIN-ENHANCED ENTERAL NUTRITION AND METABOLOMICS IN CRITICALLY TRAUMA AND SURGICAL PATIENTS	UWSC14460	—	7,009
93.847	REGULATION OF WHITE ADIPOSE TISSUE FUNCTION AND ENERGY BALANCE BY BREASTMILK ANTIBODIES	UWSC13816	—	25,997
93.855	SEATTLE TUBERCULOSIS RESEARCH ADVANCEMENT CENTER	UWSC13843	—	50,176
93.855	SEXUALLY TRANSMITTED INFECTIONS (STI) COOPERATIVE RESEARCH CENTER (CRC) - SYPHILIS VACCINE TO PROTECT AGAINST LOCAL AND DISSEMINATED T. PALLIDUM INFECTION	UWSC13625	—	97,275
93.855	SEXUALLY TRANSMITTED INFECTIONS (STI) COOPERATIVE RESEARCH CENTER (CRC) - SYPHILIS VACCINE TO PROTECT AGAINST LOCAL AND DISSEMINATED T. PALLIDUM INFECTION	UWSC11421	—	(81,879)
93.U34	SEXUALLY TRANSMITTED INFECTIONS IMPACT RESEARCH CONSORTIUM (STIIRC)	AWOA	—	66,463
93.853	SIGNALING PATHWAYS THAT MODULATE NEURONAL ACTIVITY	UWSC13828	—	143,587
93.855	STATISTICAL ISSUES IN AIDS RESEARCH	UWSC13695	—	173,731
93.859	STATISTICAL METHODS TO ENHANCE REPRODUCIBLE MICROBIOME DISCOVERY	UWSC13696	—	44,505
93.396	STROMAL FOXF2 SUPPRESSES PROSTATE CANCER PROGRESSION	UWSC14489	—	24,704
93.855	STRUCTURAL AND DYNAMICS TRAITS UNDERLYING PHENOTYPIC VARIATION IN HIV-1 ENV	UWSC14297	—	34,053
93.839	STRUCTURAL AND NUCLEOTIDE VARIATION AS GENOMIC RISKS FOR VENOUS THROMBOSIS: TOPMED AND INVENT COLLABORATION	UWSC14327	—	54,681
93.855	STRUCTURE-BASED DESIGN OF BROADLY PROTECTIVE CORONAVIRUS VACCINES - COVID-19	UWSC14190	—	39,082
93.399	THE CASCADE CLIMB: CERVICAL CANCER PREVENTION IN WOMEN LIVING HIV RESEARCH MOBILIZATION BASE	AWOA	—	28,757
93.399	THE CASCADE CLIMB: CERVICAL CANCER PREVENTION IN WOMEN LIVING WITH HIV RESEARCH MOBILIZATION BASE	UWSC14160	—	169,606
93.866	THE DOGS AGING PROJECT: GENETIC AND ENVIRONMENTAL DETERMINANTS OF HEALTHY AGING IN COMPANION DOGS	UWSC13736	—	158,498
93.394	THE EFFECTS OF MODERATE-TO-VIGOROUS EXERCISE ON BIOMARKERS OF ANGIOGENESIS, INVASION, AND CHRONIC STRESS IN OVARIAN CANCER SURVIVORS	UWSC13958	—	5,885
93.865	THE IMPACT OF VAGINAL MICROBIOTA ON CERVICAL DENDRITIC CELLS: AN OBSERVATION STUDY OF WOMEN FROM SUB-SAHARAN AFRICA AT HIGH RISK FOR HIV ACQUISITION			
93.855	THE REGULATORY ROLE OF NATURAL PROGESTERONE IN BARRIER IMMUNITY	UWSC13663	—	22,713
93.855	THE ROLE OF SEMEN IN INDUCTION OF PATERNAL-SPECIFIC TOLERANCE DURING PREGNANCY	UWSC14177	—	178,160
12.420	THERAPEUTIC TARGETING OF NEUROENDOCRINE PROSTATE CANCER	UWSC13671	—	66,149
93.350	TRANSLATING AABS FOR SCLC EARLY DETECTION AND TREATMENT	UWSC13866	—	9,787
93.855	UNIVERSITY OF WASHINGTON ARBOVIRAL RESEARCH NETWORK (UWARN)	UWSC13470	—	94,243
93.855	UNIVERSITY OF WASHINGTON ARBOVIRAL RESEARCH NETWORK (UWARN)	UWSC12068	—	(3,949)
93.855	UNIVERSITY OF WASHINGTON/FRED HUTCH CENTER FOR AIDS RESEARCH	UWSC13870	—	25,493
93.855	UNIVERSITY OF WASHINGTON/FRED HUTCH CENTER FOR AIDS RESEARCH	AWOA	—	13,999
93.855	UNIVERSITY OF WASHINGTON/FRED HUTCH CENTER FOR AIDS RESEARCH	UWSC12998	—	39,067
93.855	UNIVERSITY OF WASHINGTON/FRED HUTCH CENTER FOR AIDS RESEARCH	UWSC13697	—	122,716

FRED HUTCHINSON CANCER CENTER
Schedule of Expenditures of Federal Awards
Year ended June 30, 2023

Federal ALN or Grant	Pass-through Funds – Department of Health and Human Services and Other Federal Agencies	Passed-through entity or award identifying number	Passed-through to subrecipients	Expenditures
93.855	UNIVERSITY OF WASHINGTON/FRED HUTCH CENTER FOR AIDS RESEARCH	UWSC13701	\$ —	66,814
93.855	UNIVERSITY OF WASHINGTON/FRED HUTCH CENTER FOR AIDS RESEARCH	UWSC13702	—	18,103
93.855	UNIVERSITY OF WASHINGTON/FRED HUTCH CENTER FOR AIDS RESEARCH	UWSC13723	—	16,665
93.855	UNIVERSITY OF WASHINGTON/FRED HUTCH CENTER FOR AIDS RESEARCH	UWSC13951	—	15,117
93.855	UNIVERSITY OF WASHINGTON/FRED HUTCH CENTER FOR AIDS RESEARCH	UWSC14446	—	13,643
93.U33	UNIVERSITY OF WASHINGTON/FRED HUTCH CENTER FOR AIDS RESEARCH - IRC CORE	AWOA	—	4,023
93.855	UNIVERSITY OF WASHINGTON/FRED HUTCH CENTER FOR AIDS RESEARCH - RONGVAUX	AWOA	—	2,051
93.855	UNIVERSITY OF WASHINGTON/FREDD HUTCH CENTER FOR AIDS RESEARCH	UWSC12576	—	(350)
93.310	USING COVID-19 TESTING AND RISK COMMUNICATION STRATEGIES TO ACCELERATE STUDENTS RETURN TO SCHOOL	UWSC13827	—	192,172
93.847	UW NUTRITION OBESITY RESEARCH CENTER	UWSC13850	—	100,676
93.855	UW/FH CENTER FOR AIDS RESEARCH: USING EMPM TO MAP POLYCLONAL ANTIBODY RESPONSES AFTER VACCINATION WITH HIV ENV VACCINE	UWSC14346	—	7,160
93.279	WAKAYA: RISING UP FOR CHOCTAW YOUTH HEALTH	UWSC14357	—	6,145
93.351	WASHINGTON NATIONAL PRIMATE RESEARCH CENTER	AWOA	—	10,784
93.351	WASHINGTON NATIONAL PRIMATE RESEARCH CENTER	UWSC14086	—	43,345
93.846	WELLSTONE MUSCULAR DYSTROPHY SPECIALIZED RESEARCH CENTER (SEATTLE)	UWSC 13893	—	69,183
93.846	WELLSTONE MUSCULAR DYSTROPHY SPECIALIZED RESEARCH CENTER (SEATTLE)	UWSC13893	—	174,536
	UNIVERSITY OF WISCONSIN:			
93.855	ANTICIPATING AND RAPIDLY RESPONDING TO RESPIRATORY VIRUS OUTBREAK WITH CONTINUOUS AIR SAMPLING IN K-12 SCHOOLS	0000002727	—	12,696
12.420	COMPREHENSIVE LIQUID BIOMARKER FOR PREDICTING EARLY RESISTANCE TO ANDROGEN RECEPTOR SIGNALING INHIBITORS IN METASTATIC PROSTATE CANCER	0000001467	—	25,788
	VAN ANDEL RESEARCH INSTITUTE:			
93.394	DETECTION AND PROGNOSIS OF EARLY-STAGE PANCREATIC CANCER BY INTERDEPENDENT PLASMA MARKERS	V544-CR1-1	—	23,180
	VANDERBILT UNIVERSITY MEDICAL CENTER:			
93.837	GENOME-WIDE ASSOCIATION STUDY OF CORONARY ARTERY DISEASES IN INDIVIDUALS OF AFRICAN ANCESTRY	VUMC99059	—	14,913
93.393	UNCOVERING COLORECTAL CANCER ETIOLOGY AND BIOLOGY BY INTEGRATING PROTEOMICS WITH OTHER OMICS DATA	VUMC112014	—	2,333
	WASHINGTON STATE UNIVERSITY:			
93.837	CELL CYCLE PROTEINS AS KEY REGULATORS OF CARDIAC CHEMOSENSITIVITY	136924 SPC002649	—	10,083
93.837	CELL CYCLE PROTEINS AS KEY REGULATORS OF CARDIAC CHEMOSENSITIVITY	136924-WSU001149	—	3,889
	WASHINGTON UNIVERSITY IN SAINT LOUIS:			
12.420	ASSESSMENT OF CLONAL HEMATOPOIESIS AND ITS RELATIONSHIP TO CARDIOVASCULAR DISEASE IN HODGKIN LYMPHOMA SURVIVORS	WU-23-0059	—	9,773
93.393	OBESITY, SEDENTARY BEHAVIORS, AND DIET QUALITY FOR PREVENTION AND EARLY DETECTION OF EARLY-ONSET COLORECTAL NEOPLASIA	WU-22-0036	—	13,228
	WEILL CORNELL MEDICAL COLLEGE QATAR:			
93.U35	NEUTRALIZING AND NON-NEUTRALIZING ANTIBODY EFFECTOR FUNCTIONS IN HIV INFECTED CHILDREN	AWOA	—	169,371
	WESTAT:			
93.U28	DEVELOPMENT AND PSYCHOMETRIC TESTING OF A PEDIATRIC CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD) SYMPTOM SCALE (PCSS)	75N91020F00087	—	3,054
	YALE UNIVERSITY:			
93.395	SUPPLEMENTS TO UM1 AWARDS FOR NCI'S EXPERIMENTAL THERAPEUTICS CLINICAL TRIALS NETWORK (ETCTN) TO SUPPORT BIOMARKER ASSAY AND PRECLINICAL EVIDENCE GENERATION FOR ETCTN STUDIES			
93.398	TRANSDISCIPLINARY RESEARCH IN ENERGETICS AND CANCER (TREC) TRAINING GRANT	CON-80003472(GR114157)	—	92,162
93.398	TRANSDISCIPLINARY RESEARCH IN ENERGETICS AND CANCER (TREC) TRAINING GRANT	CON-80003392(GR114619)	—	13,656
93.397	TRANSDISCIPLINARY RESEARCH IN ENERGETICS AND CANCER (TREC) TRAINING GRANT	CON-80003923 (GR118203)	—	85,904
93.397	VICTORY EARLY CLINICAL TRIALS CONSORTIUM - ADMINISTRATIVE SUPPLEMENT	GR111711 (CON-80002827)	—	68,644
	Grant total - Pass-through Research and Development Funds		1,749,168	55,614,875
12	DEPARTMENT OF DEFENSE		—	658,099
17	DEPARTMENT OF LABOR		—	—
47	NATIONAL SCIENCE FOUNDATION		—	114,059
93	DEPARTMENT OF HEALTH AND HUMAN SERVICES / NATIONAL INSTITUTES OF HEALTH		1,749,168	54,842,717
	Grant Total – Direct and Passthrough Research and Development Funds		\$ 117,612,037	475,712,072

See accompanying notes to schedule of expenditures of federal awards.

**FRED HUTCHINSON CANCER CENTER
UNIFORM GUIDANCE FOR FEDERAL AWARDS**

Notes to Schedule of Expenditures of Federal Awards

Year ended June 30, 2023

(1) Basis of Presentation

The accompanying schedule of expenditures of federal awards (the Schedule) includes the federal award activity of Fred Hutchinson Cancer Center (Fred Hutch) under programs of the federal government for the year ended June 30, 2023. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200 (2 CFR 200), *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Because the Schedule presents only a selected portion of the operations of Fred Hutch, it is not intended to and does not present the complete consolidated statement of financial position, statement of activities, cash flows, or functional expenses of Fred Hutch.

(2) Summary of Significant Accounting Policies

Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. Negative amounts shown on the Schedule represent adjustments or credits made in the normal course of business to amounts reported as expenditures or passed through to subrecipients in prior years. Fred Hutch has elected not to use the 10-percent de minimis indirect cost rate allowed under the Uniform Guidance.

FRED HUTCHINSON CANCER CENTER
Schedule of Findings and Questioned Costs
Year ended June 30, 2023

(1) Summary of Auditors' Results

- a. Type of report issued on whether the consolidated financial statements were prepared in accordance with generally accepted accounting principles: **Unmodified**
- b. Internal control deficiencies over financial reporting disclosed by the audit of the financial statements:
 - Material weaknesses: **No**
 - Significant deficiencies: **None Reported**
- c. Noncompliance material to the financial statements: **No**
- d. Internal control deficiencies over major programs disclosed by the audit:
 - Material weaknesses: **No**
 - Significant deficiencies: **None reported**
- e. Type of report issued on compliance for major programs: **Unmodified**
- f. Audit findings that are required to be reported in accordance with 2 CFR 200.516(a): **No**
- g. Major programs:
 - Research and Development Cluster – various Assistance Listing numbers
- h. Dollar threshold used to distinguish between Type A and Type B programs: **\$3,000,000**
- i. Auditee qualified as a low-risk auditee: **Yes**

(2) Findings Relating to the Financial Statements Reported in Accordance with *Government Auditing Standards*

None

(3) Findings and Questioned Costs Relating to Federal Awards

None